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ABSTRACT
PREDICTORS OF HEALTHCARE COST IN A WISCONSIN ACUTE LEUKEMIA
POPULATION: UTILIZATION OF A STATE-LEVEL ALL PAYER CLAIMS
DATABASE
by
Patricia A. Steinert, MBA
The University of Wisconsin-Milwaukee, 2012
Under the supervision of Ron Cisler, PhD
Understanding cost predictors of low incidence high cost cancers is increasingly
important as the U.S. attempts to control health care costs. Acute myeloid and acute
lymphoblastic leukemia are hematologic cancers requiring high cost care.
Using Anderson’s model of health care utilization this study explores the
influence of patient and community factors on health care costs. Insurance claims cost
data obtained from the Wisconsin Health Information Organization provided a sample of
837 acute leukemia patients from April, 2009 and June, 2011. Total, ancillary, inpatient,
outpatient, pharmacy and professional services costs were analyzed using a GLM gamma
log link regression model to identify cost predictors. The added influence of patient and
community enabling factors over patient characteristics and need for services was
analyzed with hierarchical regression.
Study findings include: (1) Predisposing characteristics of acute leukemia patients
may not follow the commonly reported direction of cost where higher cost was associated
with older age and female gender. Instead their costs are expected to be higher in
younger, male patients; (2) As expected, treatment with hematopoietic stem cell
ii

transplant (HCT) and increased severity of disease represent significant cost drivers and
strongly influence higher costs; (3) Community enabling resources influence cost where
academic medical centers are associated with higher cost and providers located in areas
of higher poverty are associated with lower cost; and (4) Costs related to different service
types, i.e. inpatient, outpatient, etc., may not follow the same trends and result in
important differences in findings. While this creates complexity in assessing cost drivers
it can provide the opportunity for cost interpretation and decision making specific to
service type.
Implications of study findings support the need for healthcare service research of
rare diseases; further exploration of the relationship between treatment choice and cost as
well as treatment disparities between providers and their locations; and the importance of
clarity in service type cost.
Future research opportunities would include linking cost data to clinical outcomes
data; expanding the cost dataset longitudinally to accommodate more patient records
along with a longer timeline of data for each; and sub analyses of potential interactions
between variables.
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CHAPTER 1: Introduction
1.1. Study Background.
Rapidly increasing health care costs are a significant concern in the United States.
In 2009, the Federal Centers for Medicare and Medicaid reported the costs associated
with the health care sector of the U.S. economy accounted for 17.3% of the gross
domestic product (GDP). (www.cms.gov/National Health ExpendData) At the same
time, the U.S. has been reported to have one of the highest worldwide growth rates in
health care spending increasing from 9% of GDP in 1980 to 16% of GDP in 2008
(www.kff.org/insurance/snapshot).
While the majority of Americans have health insurance, the number covered by
private health care insurance is decreasing and the number covered by government health
insurance or uninsured is increasing. In September, 2011 the percentage of Americans
with health insurance was reported at 256.2 million, 83.7% of the population. Private
health insurance accounted for 64% of all insured with 55.3% attributed to employer
based programs, a number that has been decreasing since 2001. The percentage of
Americans covered by government health insurance programs increased to 31%; 15.9%
Medicaid and 14.5% Medicare. The number of Americans without insurance increased
to 49.9 million between 2010 and 2011, or 16.3 percent of the population
(www.census.gov/hhes). The Bureau of Labor Statistics report a 6% increase in
individual healthcare spending between 2008 and 2010; primarily driven by a 10.8%
increase in the cost of health insurance (www.bls.gov/news.release/cesan).
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Finding solutions for health care cost accountability, transparent reporting and a
reduction of rapidly increasing health care costs is consistently noted as a high priority by
many U.S. government leaders and agencies (www.acponline.org/advocacy;
www.healthcare.gov; www.ahrq.gov/research). The Patient Protection and Affordable
Care Act, signed into law on March 23, 2010 by President Obama, has been designed to
expand health care coverage, control health care costs and to improve the health care
delivery system (www.kff.org/healthreform). The new legislation is controversial and it
is unknown if it will be effective in reducing the rate of growth in the health care market
in the short or long term.
1.2. Leukemia Cost.
In Facts 2012 the Leukemia and Lymphoma Society report new cases of
leukemia, lymphoma and myeloma are expected to represent nine percent of the
approximate 1.6 million new cancer cases diagnosed in 2011 with 12.5 percent of new
cases attributed to leukemia alone. Diseases such as acute myeloid leukemia and acute
lymphoblastic leukemia require high cost care in order to achieve long term, disease free
survival. Use of prolonged hospital care, high levels of medical technology and
specialized health care services contribute to the high cost of treatment (Yu, 2006).
Expensive chemotherapy regimens along with the potential for hematopoietic stem cell
transplant create a continuum of cost starting from initial diagnosis through disease
remission. Ongoing oversight and maintenance treatments extend the use of health care
services indefinitely.

3

1.3. Problem Statement.
As the U.S. health care system debates policies to control health care cost, it
becomes increasingly important to understand the drivers of high cost care. Exploring
cost predictors of low incidence, low prevalence but high cost cancers is important to
both identify and better understand the underlying healthcare utilization and cost drivers.
This study proposes to investigate both patient and community variables that may
influence the cost of treatment of an acute leukemia population in Wisconsin.
1.4. Study Objective and Specific Aims.
The primary objective of this study is to explore the influence of certain patient
demographic, provider demographic and socioeconomic variables on health care claims
costs associated with a Wisconsin leukemia population identified within the State of
Wisconsin all payer claims database and, through the utilization of this database, attempt
to identify factors that are predictive of higher cost. The study examines patients with the
diagnosis of acute lymphoblastic leukemia, acute myeloid leukemia, and are present in
the Wisconsin Health Information Organization (WHIO) database from April 1, 2009
through June 6, 2011. WHIO is an all payer claims database representing residents of
the State of Wisconsin. An underlying objective of the study is to assess the usefulness of
the WHIO datamart for cost research.
In order to differentiate cost predictors related to service types, the study will
examine claims costs associated with a the diagnosis of acute leukemia through six
criterion variables: (1) Total claims cost; (2) Ancillary claims cost; (3) Inpatient claims
cost; (4) Outpatient claims cost; (5) Pharmacy claims cost; and (6) Professional claims
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cost. The study will investigate both by billed cost (i.e., what is charged to the patient)
and standard cost (i.e., a WHIO defined standardization definition) in an effort to
determine if the two costs are different. Diagnosis related claims costs are identified
through WHIO defined episode treatment groups (ETG) and are the sum of all costs
associated with the leukemia episode. Throughout this paper, the diagnosis-cause cost
analyzed in this study is referred to simply as ‘cost’. The definition of the WHIO defined
episode treatment groups is outlined in Appendix B.
Whether cost is investigated using billed cost, standard cost or paid cost as a
criterion variable is dependent on the perspective of the study. A study that is interested
in the patient perspective may use billed cost. A study interested in using a closer
definition to actual cost may choose standard cost. A study that has a business
perspective may use paid cost. Billed cost, paid cost and standard cost is available in the
WHIO datamart, but only billed cost and standard cost were available for use in this
study. Standard cost is calculated to adjust for variations related to insurance contracting,
region and disease severity and comorbidity. In a 1982 article, Finkler identifies the use
of standard cost as best if the perspective of the study is real operational cost or resources
used, but states that if the perspective of the study is the cost to the patient, billed cost is
acceptable (Finkler, 1982). While the patient perspective is considered important overall,
use of standard cost is more common in health cost studies.
The study has three specific aims:
Aim 1: To determine if patient predisposing characteristics of age and gender, the
patient need factors of treatment type and treatment episode severity and the enabling
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resources of county of residence socioeconomics, type of payer, are predictive of cost. In
addition, to examine whether the type of health care provider, academic medical center or
non-academic medical center, or its location socioeconomics are predictive of cost.
Aim 2: Using the optimal statistical model; to examine their influence on the cost
criterions.
Aim 3: To investigate whether patient and community enabling resources; defined as
provider type and location socioeconomics, patient enabling resources; defined as payer
type and patient residence socioeconomics have added influence on cost over patient
level predisposing characteristics: defined as age, gender and length of follow up and
patient need; defined as episode treatment severity and treatment type.
1.5. Scientific Significance.
Prior theories of health care utilization identify patients need for care as a
determining factor in use of health care services. In addition, people who use more
health care have been shown to incur more health care costs (Andersen, 1995). An acute
leukemia population will have a high need for healthcare, is expected to have high
utilization of health care services and incur high cost. These factors create a financial
burden to the patient, the provider and the community. Less understood are the patient
and community factors associated with acute leukemia patients and their providers which
may be predictive of higher cost. Knowledge of key factors that influence these costs
will benefit decision making at the patient, provider, and policy making level.
Concern over increases in health care expenditures has created an immediate need
to better understand costs and cost drivers in the health care system. This study of low
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incidence, high cost patients will provide needed information about groups that may not
be immediately assessed. Through the examination of factors that influence cost, this
study will help identify if certain determinants can be used to better calculate the value of
treatment for these diseases, allowing more informed resource allocation decision
making.
1.6. Research Questions and Hypotheses.
This study uses data from an all payer claims database and multivariate regression
modeling as a tool to identify whether patient characteristics, need and enabling factors
and community factors are significant predictors of health care cost in a Wisconsin
leukemia population. Specific research questions are:
1. Does the patient’s age and gender, episode severity level, type of treatment and type
of payer predict health care claims cost? Does where a patient lives and the
socioeconomics of their U.S. County of residence predict health care claims cost? Do the
type of provider and its location predict health care claims cost? Are any variables more
useful in predicting the claims cost criterion?
Hypotheses: A patient’s age, type of treatment, episode severity level is each expected to
be significantly predictive of cost. Increases in each of these factors have been shown to
increase cost. A public payer, lower patient socioeconomics and lower provider
socioeconomics are also expected to be predictive of an increase in cost. Finally, an
academic provider is expected to have higher costs when compared to a community
provider.
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2. How strong is the influence of each predictor on the cost criterion?
Hypotheses: While each is expected to be measurably predictive of the cost criterions,
some variables, such as age, treatment, and disease severity level are expected to have a
stronger influence when compared to others, such as payer type and gender. Provider
type and location may have a slight influence on cost due to the differences in regional
socioeconomics and organizational insurance contracting where higher costs are
associated with academic medical centers and wealthier communities.
3. Does adding patient and community enabling resources, over and above patient
predisposing characteristics and need for services predictors, significantly add to the
predictability of the model, and if so, how strong is their influence?
Hypotheses: It is expected that, due to differences in patient’s healthcare insurance and
socioeconomics as well as regional socioeconomics and insurance contracting, the patient
and community enabling resources predictors will significantly add value to the model.
Health care cost data can be difficult to obtain as well as organize for research
purposes. An underlying intent of this study is to assess the usefulness of this type of
administrative database to address health care cost research questions.
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CHAPTER 2: Literature Review
Studies of economic evaluation and health services were identified in a search
through PubMed and the Cochran Collaboration between years 2004 through 2011. (Key
words: acute lymphoblastic leukemia, acute myeloid leukemia, hematopoietic stem cell
transplant, chemotherapy, economic evaluation, health care cost, health services cost
methodology, zip code socioeconomics).
2.1. Theoretical Framework.
Prior health determinants research is used as a theoretical basis for this study.
While the theories may not directly address cost as an outcome, its presence is implicit in
the areas of access, quality and resource allocation. Each theory supports the need to
investigate and better understand the role of cost in health care utilization and decision
making for the patient, provider and the community.
2.2. Behavioral Models of Health Care Utilization.
Aday proposed a comprehensive framework for health services research focusing
on pathways that influence community and patient health outcomes (Aday, 2001). This
conceptual model incorporates both a community and patient perspective with a goal of
integrating health services and public health research. It integrates concepts of system
structure and process, intermediate outcomes with a goal of an ultimate health outcome.
In this model health policy, federal, state and local, is the highest level concept. Level
two relates to structural areas and includes the health care delivery system (availability,
organization, financing), population at risk (predisposing, enabling, need) and
environment (physical, social, economic). Level three focuses on the process areas of
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realized access to care (utilization, satisfaction) and health risk (environmental and
behavioral). Level four identifies the first intermediate outcome of effectiveness (clinical
and population). The second intermediate outcome level, five, is equity (procedural and
substantive) and efficiency (production and allocative). Level six is the final, ultimate
outcome of health for both the patient and the community. Each part of the conceptual
model provides defined areas for health services research at both the patient and
community level. By including micro and macro level concepts, the framework provides
the ability to investigate both the detail of an area of interest and then link it to the public
health focus of community health.
Aday used this conceptual base to create a framework for studying vulnerable
populations. In this model, the areas of focus include; social and economic policy,
community oriented health policy, medical care and public health policy along with
ethical norms and values. Linkages between patient and community risk factors are
illustrated along with variables that can be predictive of vulnerability for poor health
outcomes. Health policy is identified as a mediator for the potential of positive versus
negative health outcomes.
Aday’s framework built on Anderson’s 1960’s Behavioral Model of Health
Services Use which assessed determinants of health care utilization. (Anderson, 1968)
With the intention of promoting equitable access to health services, Anderson (figure 2.1)
investigated factors related to why families used health services. This behavior model
proposes that an individual’s use of health care can be attributed to certain individual and
community or organizational predisposing factors that will either increase or decrease
utilization. Predisposing factors are related to biology; such as age and gender, social
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structure; such as education, occupation, ethnicity, environment and culture, and, health
beliefs; such as attitudes, values and knowledge. In addition, both individual and
community level resources are necessary to support the use of health care. These include
factors such as income, health insurance, transportation, and availability of health care
personnel and facilities. Finally, use of health care services will be influenced by the
individual’s perceived/evaluated need for services as well as their ability to access to
health care resources, work within the health care system and effectively manage their
clinical problem.
Figure 2.1 Anderson’s behavioral model

Anderson, R.M. (1995). Revisiting the behavioral model and access to medical care: Does it matter?
Journal of Health and Social Behavior; Social Science Module, Mar, 36, 1.

The models recognize that economic factors at both the individual and the
community level, along with appropriate allocation of healthcare resources need to be
addressed for improvement in population health. This study will further explore how
patient, provider and community factors impact high utilization and costs of health
services.
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2.3. Health Services Utilization Database Research.
In 2003, Hay investigated cost hospital cost drivers using state-level data.
Utilizing data from a representatively large U.S. health insurance plan, this article
identifies a number of characteristics that contribute to inpatient costs; local area per
capita wages and incomes, characteristics of the physician market, hospital technology,
and hospital occupancy and case-mix severity. Other factors such as staff shortages and
an economic slowing are noted to contribute to cost pressures.
Schneeweiss and Avorn reviewed the utility of large healthcare databases for
epidemiologic health care research, focusing on pharmaceuticals (Schneeweiss and
Avron, 2005). They conclude that electronic medical record systems have a great
potential for research investigating comparisons, longitudinal data and clinical
epidemiologic data. They note that care must be given to the design of studies to allow
for the system limitations and potential sources of bias such as incomplete records,
miscoding, incorrect record linkage, etc. As clinical detail and accountability increase,
these systems are expected to become more useful to outcomes research.
Motheral and her colleagues provide a checklist for retrospective database studies
(Motheral, Brooks, Clark, Crown, Davey, Hutchins, Martin & Stang, 2003). This article
lists 27 questions that give guidance for designing a research study using a retrospective
database specifically using medical claims or encounter databases. These questions help
to guide and decision about the study data, study methods and conclusions. This study
incorporated some of these conclusions into its study design, methods and conclusions.
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2.4. U.S. Census Data and Socioeconomic Inequalities.
Geronimus and Bound in their 1998 article of using census-based aggregate
variables as proxies for individual socioeconomics discuss the timing of census data,
when it was collected, as well as the level of aggregation of the data (Geronimus and
Bound, 1998). They found that while investigators can comfortably use census data that
can be up to 20 years old, it is limited in use for individual level interpretation. They
conclude that the aggregate variables available through geocoded data should not be
viewed as proxies for the individual level construct because the aggregate variable will
tend to be larger than the micro level variable due to biases related to correlation with
other factors of the geographic region, i.e. income, race, etc. These variables need to be
interpreted as an area-based, rather than an individual-based, constructs.
Kreiger and colleagues as part of the Public Health Disparities Geocoding Project
published a series of articles related to the usefulness of US census data to investigate US
socioeconomic inequalities. One of the articles investigated whether choice of area-based
measurement or geographic level of measurement impact results of mortality and cancer
incidence outcomes (Kreiger, Chen, Waterman, Soobader, Subramanian & Carson,
2002a). Choice of area-based measures should be related to the geographic areas
socioeconomic position (SEP) and defined through variable that could meaningfully
summarize the area’s socioeconomic conditions and be robust over time and between
regions. Variables included; occupational class, income, poverty, wealth, education and
crowding. Geographic level was defined as census block, census tract and zip code.
Results showed that measures of economic deprivation were most robust. The authors
identify the usefulness of area-based socioeconomic measures when used with
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meaningful geographic concepts but not as proxies for individual socioeconomic data.
They identify the U.S. census measure of ‘percentage of persons living below the US
poverty line’ as a variable that meets the criteria of economic deprivation, meaningful
across regions and over time, and easily understood. In a separate 2002 article these
authors discuss spatiotemporal difficulties associated with the use of zip code data and
US census data. The authors caution researchers using geocoded data to clearly identify
any spatiotemporal mismatches between the study dataset and the U.S. census variable
(Kreiger, Chen, Waterman, Soobader, Subramanian & Carson, 2002b).
In 2005 Kreiger and colleagues investigated a method of routine monitoring of
socioeconomic health disparities using census tract poverty data (Kreiger, Chen,
Waterman, Rehkopf & Subramanian, 2005). The percentage of persons living below the
U.S. poverty line variable was used in census tract groups and provided a cost-efficient
method of assessment that can be applied to health outcomes within the region and across
the US. The authors argue if the US public health surveillance data were geocoded, this
method would provide a good mechanism for routine assessment of socioeconomic-based
health disparities.
2.5. Cancer: Epidemiology and Cost.
Cancer is the second most common cause of death in the U.S.; with an estimated
577,000 deaths expected in 2012 (www.cancer.org/acs/groups). Cancer impacts the lives
of over 11 million Americans; it does not discriminate by age, ethnicity, income or region
(www.srab.cancer.gov).
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Since the beginning of this century, the overall incidence and death rates of cancer
have been decreasing; a result related to early detection, cancer prevention and better
treatment options. In The Annual Report to the Nation on the Status of Cancer, 19752007, Kohler and colleagues found a decrease in the overall incidence of cancer in the
U.S. population, but noted that due to the expected increase in life expectation the
absolute number of individuals diagnosed with cancer is expected to increase creating an
increase in demand for cancer related health care services (Kohler, Ward, McCarthy,
Schymura, Ries, Eheman, Jemal, Anderson, Ajani & Edwards, 2011). The authors point
out the need for effective management of these diseases through not only prevention,
detection treatment and survivorship but also the protection of resources necessary to
provide good quality care. They conclude that utilization of quality population-based data
systems and translation of evidence-based clinical and basic research findings are critical
to sound public policy decisions for cancer.
Using patient-reported demographic and socioeconomic data from the Social and
Economic Supplement to the Census Bureau’s Current Population Survey, Clegg and
colleagues reported cancer-related disparities linked to individual-level socioeconomic
status for all combined cancers as well as the specific cancers of lung, breast, prostate,
cervix and melanoma (Clegg, Reichman, Miller, Hanky, Singh, Lin, Goodman, Lynch,
Schwartz & Chen, 2009). Results showed, for each of the major cancer diagnoses,
significant differences in incidence rates from self-reported data of education level,
family income and poverty status. The authors note the importance of differentiating
between patient level characteristics and community level characteristics, particularly if
measuring a similar construct such as socioeconomic status. They conclude that social

15

disparities in cancer incidence may be related to socioeconomic and demographic
differences in cancer-related risk factors and behaviors, that disparities in health care
access may contribute to different types and stages of care and individuals with lower
SES and educational level are more likely to have higher rates of cancer risk factors.
The American Society of Clinical Oncology, Meropol and colleagues issued a
guidance statement regarding the cost of cancer care (Meropol, Schrag, Smith, Mulvey,
Langdon, Blum, Ubel & Schnipper, 2009). The statement recognizes that while better
prevention, detection and treatment have reduced the cancer death rate, costs of cancer
treatment have steadily risen and continue to grow rapidly creating an unsustainable
financial burden to all levels of cancer care. The guidance statement makes the following
recommendations: recognizes that physician-patient discussions regarding cost of care
are an important, a need for communication support tools for oncology providers related
to cost of care, the development of educational resources about the high cost of cancer
care. This article identifies the need for a clear understanding of cost drivers in the
cancer care system so that all patients can get access to, and are able to afford, highquality cancer care.
In countries with centralized government managed health care, such as Canada,
the Netherlands, Europe, there are studies that address the cost of diseases directed at the
appropriate use of health care resources. However, the decentralized U.S. health care
delivery system has made it challenging to assess health related costs for patients,
organizations and populations. The National Cancer Institute website reports a steady
increase in U.S. spending for cancer care (www.cancer.gov). A January, 2011 study
from the Division of Cancer Control and Population Sciences projects the continued
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increase in cancer care cost with the adoption of new, more advanced treatments as
standards of care (http://progressreport.cancer.gov).
Chang and colleagues estimated the cost of cancer for patients diagnosed with
seven of the major types of cancer (Chang, Long, Kutikova, Bowman, Finley, Crown &
Bennet, 2004). This study found significant financial burden for cancer patients. Within
the groups studied, mean monthly cost of treatment ranged from $2,187 to $7,616 with
cost driven by hospitalization and an average monthly loss of 2 work days. In contrast, a
non-cancer control was shown to have an average monthly cost of $329. They note the
viable use of administrative databases to estimate both direct and indirect costs.
The most common forms of cancers are prostate, breast, lung, and colorectal
cancer. Logically, they receive both higher levels of attention and, ultimately, funding.
Cancers such as leukemia are as deadly to the patient and require expensive treatment.
Health services research for cancers with lower incidence rates is important both to
understand the financial burden of these diseases and to protect appropriate allocation of
resources. In 2010, the National Cancer Institute reported the direct cost of cancer care in
the U.S. as $124.57 billion and the direct cost of care for leukemia was equal to $5.44
billion, roughly 4.3% of total direct cost (www.cancer.gov/aboutnci/servingpeople/cancer-statistics).
2.6. Epidemiology of Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia.
Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) are
cancers of the hematopoietic system, the system of the body which produces blood cells.
These cancers are considered acute due to the rapid spread of disease; left untreated, they
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will be fatal. Common treatments for both diseases include chemotherapy, radiation and
hematopoietic stem cell transplantation.
Acute lymphoblastic leukemia (ALL) is a common hematopoietic cancer with an
estimated 5000 cases diagnosed each year. The Surveillance Epidemiology and End
Results (SEER) website of the National Cancer Institute (NCI) reports the prevalence of
ALL in the U.S. as of January 1, 2008 to be approximately 62,193 alive, 34,306 female
and 27,887 male. An estimated 20,300 individuals will be diagnosed with ALL in 2011;
8,460 female and 11,840 male, with an estimated number of deaths equal to 5,800.
Between the years 2004-2008 the overall median age at diagnosis for ALL was 13 years;
approximately 60% of individuals diagnosed with the disease are under the age of 20
years. In children, the annual incidence of ALL is approximately 9-10 cases per 100,000
with a median age at diagnosis between 2-5 years. ALL accounts for 25% of all
diagnosed childhood cancer and 75% of childhood leukemia. The overall reported 5-year
survival for 2001-2007 was 64.4% with a median age at death between 2003-2007 being
49 years of age (www.seer.cancer.gov/statistics). Treatment of ALL includes
chemotherapy, radiation and hematopoietic stem cell transplantation with all patients
initially treated with chemotherapy. Hematopoietic stem cell transplant is considered
when disease recurs or when disease characteristics at diagnosis are such that the patient
is unlikely to be cured with chemotherapy alone. Type and level of treatment is
determined by factors such as patient age, white blood cell count at diagnosis,
cytogenetics and disease status (i.e. whether in remission or with persistent leukemia
despite chemotherapy). In 2008 in the U.S., approximately 1000 allogeneic transplants
were performed for patients diagnosed with ALL, roughly 430 for pediatric patients,
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representing approximately 6% of all transplants performed
(www.cibmtr.org/summaryslides).
Acute myeloid leukemia is a hematopoietic cancer that begins in the bone marrow
and impacts cells that would develop into white blood cells. It is one of the most
common forms of leukemia in adults with average onset around 60 years of age
(www.seer.cancer.gov/statistics). In 2011, 18,100 new cases were estimated to be
diagnosed. Of those diagnosed, 9,830 are men and 8,270 are women. The number of
deaths from AML in 2011 is estimated to be 9,320. Between the years 2004-2008, SEER
data report the median age at diagnosis of AML to be 67 years of age, with roughly 70%
of all patients over the age of 55 with a 4.3/3.0 ratio of males to females. The median age
at death was 72 years of age with a male/female ratio of 3.6/2.2 per 100,000. The years
2001-2004 and 2004-2008 a slightly increasing trend was reported for both incidence
(1.8% increase) and death (0.3% increase) in the AML population.
Treatment of AML includes chemotherapy, radiation and the hematopoietic stem
cell transplant. Standard treatment of adult AML is dependent on the disease subtype but
may include combination chemotherapy, high dose chemotherapy and stem cell
transplant using either the patients cells (autologous transplant) or donor cells (allogeneic
transplant). As with ALL, type and level of treatment is determined by factors such as
patient age, white blood cell count at diagnosis, cytogenetics and disease status, whether
in remission or with persistent leukemia despite chemotherapy. In the U.S.
approximately 2500 transplants were performed for patients diagnosed with AML,
slightly over 400 for pediatric patients, representing approximately 15% of all transplants
performed (www.cibmtr.org/summaryslides).
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2.6.1. Acute lymphoblastic leukemia treatment, survival and cost.
Acute lymphoblastic leukemia is diagnosed more commonly in children versus
adults. Pui and Evans indicate that of the number of ALL cases diagnosed annually,
roughly two thirds are from the pediatric population (Pui and Evans, 2006). In children,
the rate of 5 year survival is high, currently over 80%. Assignment to the best therapy
follows a strict assessment of relapse risk with a goal of avoiding high levels of toxicity
but attaining a high cure rate. Pediatric patients are grouped into the risk categories of
standard, high and very high risk.
ALL in adults is a challenging disease with a significantly lower rate of survival
of less than 40% (Narayanan and Sami, 2011; Paulson, Szwajcer & Steftel, 2011; and
Fielding, Richards & Chopra, 2007). While most patients are able to achieve remission
through treatment, most will eventually relapse. Survival after relapse is reported to be
10-20%. Adult treatment options tend to follow the basic structure of the pediatric
program; however, due to the poor survival rate after relapse, there is a current debate
about the value of more aggressive treatment prior to relapse in the form of hematopoietic
stem cell transplant (HCT).
Schafer and Hunger compare the survival rate of adolescents and young adults
(AYA) to both the pediatric and the adult population indicating that the AYA survival
rate fall somewhere in the middle (Schafer and Hunger, 2011). While there has been
steady improvement in survival over the last few decades, they cite trials that show better
survival for AYA’s following pediatric treatment regimens. They conclude that future
research should focus on socio-political and biological factors that may impact this
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group. Stock and colleagues discuss clinical and demographic differences between the
AYA and the pediatric population which may account for differences in survival between
the groups (Stock, La, Sanford, Bloomfield, Vardiman, Ganyon, Larson & Nachman,
2008). In a letter to the editor, Kantarjian and O’Brien suggest that an analysis of
patterns of insurance coverage may be of interest in this group (Kantarjian and O’Brien,
2009). AYA’s may go through timeframes with no insurance coverage, affecting access
and consistency of health care utilization.
VanLitsenburg and colleagues provide a cost-effectiveness investigation of
pediatric ALL in chemotherapy only regimens concluding that treatment was cost
effective for patients in standard risk and medium risk groups (VanLitsenburg, Uyl-de
Groot, Raat, Kaspers & Gempke, 2011). Risk is mainly determined through levels of
minimal residual disease. However, high risk patients were excluded from the study due
to their eligibility for hematopoietic stem cell transplant and represented approximately
10% of the group.
2.6.2. Acute myeloid leukemia treatment, survival and cost.
Acute myeloid leukemia is the most common type of leukemia in adults.
Deschler and Lubbert describe the epidemiology and etiology and identify it as a
significant contributor to the number of cancer related deaths in the U.S. (Deschler and
Lubbert, 2006). For most patients the cause of disease is unknown, however age, genetic
disorders and other hematologic disease have been reported as having a link to higher
rates of mortality. AML’s incidence rate is higher for males and occurs predominantly in
adults, with over 80-85% of all cases reported in patients >15 years of age. In adults,
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AML tends to impact those >65 years of age, with over 42% reported cases. Survival is
reported to be 23% at five years if <55 and 11% if >55. Untreated disease is always fatal.
The improvement in supportive care options possibly has impacted the higher rates of
survival over the years. One conclusion of the authors identifies the ability to use
population level databases as instrumental in the ability to detect differences because of
the rarity of the disease
Redaelli and colleagues provide a literature review of the economic burden of
AML showing it to be a disease with a high cost of care affecting older adults (Redaelli,
Botteman, Stephens, Brandt & Pashos, 2004). With the aging population, incidence rates
are expected to increase. The review of the literature resulted in a selection of twenty
nine studies that met the author’s inclusion criteria. The studies offered a range of cost
type, both indirect and direct, as well as cost comparison between different treatment
regimens. They note the lack of studies from a societal perspective and state this as a
clear direction for future research.
In an article investigating the cost–effectiveness of aggressive therapy after
relapse in AML patients, Yu and colleagues compare a chemotherapy based treatment
regimen to a hematopoietic stem cell transplant (HCT) based treatment regimen (Yu,
Gau, You, Chern, Chau, Tzeng, Ho & Tsu, 2007). AML is expensive to treat due to high
rates of hospitalization and high cost treatments. They conclude, that in patients <60,
high dose chemotherapy only regimens estimated five year survival was higher than five
year survival in the allogeneic transplant group. In addition, it was more cost-effective in
the chemotherapy only group with medium risk or lower. However, they note that their
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study is based on costs of care in Taiwan and results may not be transferable to Europe or
the U.S., given the different cost structures between countries.
2.7. Leukemia in Wisconsin.
The Wisconsin Department of Health Services reports on leukemia but is not
specific to AML and ALL. Annually, approximately 832 Wisconsin residents were
reported to be diagnosed with leukemia from 2002-2006 according to the National Center
for Health Statistic’s Public Use Mortality file. In Wisconsin, leukemia is the most
commonly diagnosed cancer under the age of 15. Leukemia’s incidence rate was higher
in males than in females (19.0 per 100,000 versus 11.0 per 100,000). An average of 485
deaths from leukemia was reported each year from 2002-2006; it is the leading cause of
diseased based death in children under the age of 15, with higher mortality rates reported
in males versus females (http://www.dhs.wisconsin.gov/wcrs/pdf/cancerwi0206.pdf).
2.8. Chemotherapy.
Chemotherapy is a treatment that uses chemical components to stop the growth of
cancer cells. Some leukemia’s are treated only with chemotherapy regimens designed
using multiple factors such as type of disease, severity of disease, patient age, etc. In
AML, most patients begin treatment in induction chemotherapy with a goal of bringing
the disease into remission. If remission (CR1) is successful, most leukemia cells will be
destroyed. If it is unsuccessful additional chemotherapy treatment or hematopoietic stem
cell transplant (HCT) may be necessary
(www.marrow.org/patient/disease_and_treatment).
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In ALL, chemotherapy is the standard treatment for pediatric patients prior to
first remission (CR1); however at first remission HCT becomes a viable treatment option.
Adult ALL has not followed the same treatment guidelines as the pediatric group and
HCT is an option at diagnosis. In prior ALL studies reviewed, cost of chemotherapy was
contrasted to cost of HCT. The results of a 2007 study Orsi and colleagues concluded
that allogeneic HCT for ALL patients in CR1 improved both event-free survival when
compared to chemotherapy or autologous transplant and showed an acceptable level of
cost-effectiveness (Orsi, Bartolozzi, Messori & Bosi, 2007). However, Yu and
colleagues in a cost analysis with an acute myeloid population concluded that the costeffectiveness of high dose chemotherapy treatment was comparable to allogeneic HCT in
high risk patients, but in medium risk patients, high dose chemotherapy proved to be
more cost-effective (Yu, Gau, You, Chern, Chau, Tzeng, Ho & Tsu, 2007). In their
conclusion, they identified the need for further research in the area given their sample
size and cost differentiation. VanLitsenburg and colleagues studied the influence of new
medication and technology in a cost-effectiveness analysis of a pediatric ALL population
treated with chemotherapy only regimens (VanLitsenburg, Uyl-de Groot, Raat, Kaspers
& Gempke, 2011). This study found treatment to be cost-effective in standard and
medium risk patients. Other chemotherapy cost studies compare newer drugs entering
the market to those historically available. (Hann, Stevens, & Goldstone, 1997; Kattan,
Inoue, Giles, Talpaz, Olzer, Guilhot, Zuffa, Huber & Beck, 1996)
2.9. Hematopoietic Stem Cell Transplant.
Currently, hematopoietic stem cell transplant (HCT) is the only approved use of
stem cells for disease treatment. A hematopoietic stem cell (HSC) is a cell that has the
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ability to produce new blood and immune cells and is found in the bone marrow,
peripheral blood and umbilical cord blood. Like normal HSC’s, malignant hematopoietic
stem cells also have the capacity for self-renewal and are the cause of various leukemia’s.
While chemotherapy can successfully treat, and eliminate cancer, in some cases more
intensive treatment is required for a cure. HCT is more intensive than chemotherapy; this
treatment involves high-dose chemotherapy and irradiation followed by infusion of
hematopoietic stem cells from a suitable related or unrelated donor. Both normal and
malignant stem cells are destroyed and the infusion of hematopoietic stem cells restores
the content of the bone marrow in the person with ALL. Despite the aggressive
treatment, leukemic cells can persist or recur after HCT requiring further therapy, which
may or may not be successful at disease eradication.
The Healthcare Cost and Utilization Project (H-CUP) identified bone marrow
transplant as the procedure with the most rapidly growing cost with aggregate costs
growth of 84.9 percent between 2004 and 2007. (Stranges, Russo & Friedman, 2009)
Prior research of cost and cost-effectiveness in hematopoietic stem cell transplant has
investigated; the disease treatment (inpatient and outpatient); comparatively assessed the
introduction of a new drug or therapy option (cord blood); and the ability to identify pretransplant characteristics that impact cost. (Jacobs, Hailey, Turner & Maclean,2000; Lee,
Klar, Weeks & Antin, 2000; Lin, Lairson, Chan, Du, Leung, Kennedy-Nassar, Martinez,
Gottschalk, Bollard, Heslop, Brenner & Krance, 2010; Majhail, Mothukuri &
MacMillian, 2010; Saito, Cutler, Zahrieh, Soiffer, Ho, Alyea, Koreth, Antin & Lee, 2008)
In a 2004 article, Gajewski and colleagues reviewed the relationship between providers
and payers of HCT concluding that providers need to understand the true cost of care as
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well as be able to identify predictable and unpredictable outlier risks (Gajewski, Foote,
Tietjen, Melson, Simmons & Champlin, 2004). Ashfaq and colleagues recognized that
detailed information available regarding HCT cost exists along with some cost
effectiveness research, however, they state that there is limited evidence available related
to adults and children with acute leukemia, noting the small size of the studies and their
limited use for policy decision making (Ashfaq, Yahaya, Hyde, Andronis, Barton, Bayliss
& Chen, 2010). Other HCT cost studies have been limited to direct cost of treatment
within a single center, some extending cost to 1 year or 2 years post treatment.
Researchers have indicated a need for additional economic and quality of life studies.
(Stephens, Gramegna, Laskin, Botteman & Pashos, 2005).
During the 1990’s changes to clinical practice in HCT included the increased use
of autologous transplantation, peripheral blood transplantation, outpatient treatment as
well as the use of cord blood for donor cells. Studies conducted during this timeframe
investigated cost comparisons of these treatment related changes, concluding an overall
reduction in cost with the new treatment options. In a review of the literature, Pickard
and colleagues provided a comprehensive review of studies relating to health related
quality of life and economic evaluation in pediatric ALL (Pickard, Topfer & Feeny,
2004). While some studies address disease specific economic burden and cost
comparisons, most conclude that actual cost effectiveness analysis in the U.S. health care
sector continues to be a challenge (Majhail, Mothukuri, Brunstein & Weisdorf, 2009;
Redaelli, Botteman, Stephens, Brandt & Pashos, 2004).
There have been significant advances in the clinical outcomes of hematopoietic
stem cell transplant with a relatively large body of research investigating transplant
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outcomes and new treatment cost effectiveness. Bennett and colleagues showed
decreasing cost related to the introduction of new donor options (Bennett, Waters,
Stinson, Almagor, Pavletic, Tarantolo & Bishop, 1999). Other studies have provided
detail of how to cost and overall cost of the procedure itself. (Majhail, Mothurkuri,
Brunstein & Weisdorf, 2009; Westerman and Bennett, 1996; Waters, Bennett & Pajeau,
1998). Cordonnier and colleagues studied whether the use of reduced intensity treatment
regimens were less costly (Cordonnier, Maury, & Esperou, 2005). They found no
significant reduction in cost due to the higher rates of infection and graft versus host
disease in patients on the reduced intensity regimens.
Decision models for predicting long term outcomes and costs were reported by
Costa and colleagues (Costa, McGregor, Laneuville & Brophy, 2007). The study used a
Markov decision analysis model in an adult population with acute leukemia and
concluded that although initial transplant cost are high, the long term benefits of the
transplant when compared to a non-transplant alternative, provided incremental cost
effectiveness ratio (ICER) values that were both socially and financially acceptable.
Saito and colleagues investigated costs of allogeneic HCT with high dose regimens
(Saito, Cutler, Zahrieh, Soiffer, Ho, Alyea, Koreth, Antin & Lee, 2008). This study
provided detailed single institution cost of treatment, cost estimates for complicated and
uncomplicated HCT procedures and costs for management of specific transplant related
complications.
In a 2010 study Lin and colleagues evaluated the cost and cost effectiveness of
allogeneic peripheral blood stem cell transplantation compared to bone marrow
transplantation in pediatric patients with acute leukemia (Lin, Lairson, Chan, Du, Leung,
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Kennedy-Nassar, Martinez, Gottschalk, Bollard, Heslop, Brenner & Krance, 2010). This
study concluded that comparative economic evaluation supported bone marrow transplant
for standard-risk patients but indicated at lack of certainty for high-risk patients. The
ability to predict overall cost using pre-transplant patient characteristics was investigated
by Lee and colleagues (Lee, Klar, Weeks & Antin, 2000). Their study was unable to
identify pre-transplant characteristics; however it concluded that preventing clinical
complications could significantly impact overall cost.

CHAPTER 3: Methods
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3.1. Design.
This study is a cross-sectional secondary analysis of insurance claims data from
the Wisconsin Health Information Organization for patients diagnosed with acute
leukemia. The active WHIO data mart contains 24 months of insurance claims data,
collected over 27 months for completeness and refreshed approximately every 6 months.
The study’s conceptual models are constructed using Anderson’s healthcare utilization
model assumptions regarding the influence of patient predisposing characteristics,
enabling resources and need (Figure 3.1). Concept model 1 fits each predictor variable
into the Anderson model and its relationship to each cost criterion. Concept model 2
presents the hierarchical relationship between the grouped variables and the cost
criterion. A quantitative analysis of the data is performed using multivariate regression
methods, specifically generalized linear modeling (GLM). Predictor variables have been
identified and assessed in terms of their potential effect on the cost criterion variable
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Figure 3.1.Concept Models.
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3.2. Data.
The Wisconsin Health Information Organization (WHIO) is a state-wide
collaboration of insurance companies, health care providers, large employers and public
agencies (www.wisconsinhealthinfo.org). Starting in 2005, this group developed a Statelevel database of health insurance claims in order to provide data useful for examining
health care issues related to quality, efficiency and safety within the State of Wisconsin.
Access to the data is available through the Wisconsin Health Information Organization
Health Analytics Exchange (WHAE), a data base reporting system covering more than
247.6 million insurance claims for care to roughly 3.8 million Wisconsin residents. The
exchange began collecting data in 2008 and provides access to a rolling 27 months of
data; a total of 23.1 million episodes of care. Version 6 of the data mart (DMV6)
contains information for approximately 64.9% of the Wisconsin population. Commercial
claims represent 42% of the total, 25% are Medicaid FFS claims, 20% are Medicaid
HMO claims and 13% are Medicare claims. Additional detail regarding the DMV6 data
is provided in Appendix A.
The WHIO Health Analytics Exchange reporting system is designed for health
care organization use, not specific to research, therefore limiting the types of research
possible. For the purposes of this study, the Wisconsin Medical Society (WMS) provided
a core data set of all insurance claims for all patients with a diagnosis code of leukemia
and lymphoma, DRG 200-208, in the DMV6 data. Due to its size, the WMS data file
was filtered to include only acute leukemia diagnoses. Additional variables were
obtained directly from the WHAE reporting system. A relational database was created in
Microsoft® Access 2010 and all variables were merged by patient ID to create the final
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study dataset. The study dataset was transferred to SAS 9.3, © SAS Institute, Inc., for
data analysis.
3.3. Sample.
The study sample consists of WHIO database patients with a diagnosis of acute
myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) coded at any time
within the DMV6 data base. The WHIO-DMV6 datamart includes a population of
patients with claims submitted between the dates 4/1/2009 and 6/30/2011. The initial
dataset contained patients with any leukemia or lymphoma diagnosis which was further
filtered to the specific diagnosis of acute AML and ALL. Table 3.1 provides the
description and diagnosis codes for this sample.
Table 3.1. Lymphoma and Leukemia Diagnosis Codes.
DRG code description

Surgical code

Lymphoma and leukemia without major
O.R. procedure with mcc

820

Lymphoma and leukemia with major
O.R. procedure with cc

821

Lymphoma and leukemia with major
O.R procedure without cc/mcc

822

Medical code

Lymphoma and leukemia without major
O.R. procedure with mcc

834

Lymphoma and leukemia without major
O.R. procedure with cc
Lymphoma and leukemia without major
O.R. procedure without cc/mcc

835

CC-complications
MCC-major complications

836
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The datamart tracks patients by claims received and uses episode treatment
groups or ETG’s (Table 3.2) that assign claims to both a specific diagnosis as well as a
specific time of the event. Patients can be assigned up to three diagnoses in each episode
of care and are included in the study if an acute leukemia diagnosis was present. Service
types are used to identify where the cost was generated, i.e. inpatient, outpatient,
ancillary, professional or pharmacy.
Table 3.2.Episode Treatment Group-ID; Leukemia Episode Treatment Group.
ETG type
Leukemia without surgery

ETG-ID
85

Leukemia with surgery

86

Leukemia with active management
without surgery

87

Leukemia with active management
with surgery

88

The DMV6 data set provided claims for 12,504 unique patients with a lymphoma
or leukemia DRG as the primary, secondary or tertiary diagnosis. A further filter for the
acute leukemia ICD-9 codes identified a sample of 837 unique patients with a diagnosis
of acute lymphoblastic or acute myeloid leukemia. (Table 3.3)
Table 3.3.ICD-9 CM Code for Acute Leukemia
Diagnosis

ICD-9 CM code

Acute lymphoblastic leukemia

204.xx

Acute myeloid leukemia

205.xx
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The flow chart identifying datamart patients with acute leukemia is provided in
Figure 3.2.
Figure 3.2. Flow Chart of Acute Leukemia.
Patients included in WHIO data
mart, 4/1/2009-6/30/2011
N=3,864,345
Exclude patients with DRG’s other
than 200.xx-208.xx
N=3,851,841
Patients with a diagnosis of
leukemia or lymphoma included in
the WHIO DMV6 datamart
(DRG 204-205)
N=12,504

Exclude patients with non-acute
diagnosis
N=11,670

Patients with a diagnosis of acute
leukemia
N=837

3.4. Variables.
Variables that were reviewed for inclusion into the study models are listed in
Table 3.4. Model variables are included based on their potential influences on healthcare
cost on the patient and community level as well as their availability in the datamart.
Healthcare outcomes are known to be influenced by patient and disease related along
with treatment related factors. However, a limitation of the WHIO datamart is that it does
not provide data specifically related to clinical outcome and the variables used in this
study are limited to those available within the datamart. Patient age and gender are
included; unfortunately race is not available in the data base and cannot be included in
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the analysis. All study variables are assessed for their potential influence on healthcare
cost through a review of prior literature. Each variable has been reviewed for definition
within the database, availability and redundancy. Overall availability and completeness
of a variable has been assessed for its impact and usefulness for the study.
3.5. Measurement.
3.5.1. Criterion variable: cost.
The criterion variable, cost, is defined by total cost, ancillary cost, inpatient cost,
outpatient cost, pharmacy cost and professional cost. Cost data for the study is available
in two ways: (1) Cost of service billed, defined as provider charges; and (2) Standard
cost, defined through a standard pricing methodology that attempts to smooth out cost
differences caused by factors such as contractual agreements and region. Because this
study is interested in both patient and community perspective the cost of services billed
and the standard cost will be modeled in the analysis. The claims cost criterion is defined
as a diagnosis-specific cost and represents all claims received for a patient where an acute
leukemia diagnosis code has been used for any of the three diagnoses codes in the WHIO
datamart. All costs used in the study are associated with insurance claims and will be
referred to simply as ‘cost’.
3.5.2. Predictor variables.
3.5.2.1. Predisposing characteristics
Patient predisposing characteristics predictor variables of cost are defined as (1).
Patient age (i.e., age recorded in the datamart); (2) Patient gender (i.e., gender recorded in
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the datamart); and (3) Length of follow up (i.e., calculated as the difference in the number
of days between the start of service date and end of service date).
Age has been linked to better outcomes in a number of studies. (Deschler and
Lubbert, 2006; Lee, et.al, 2000, Saito, Zahrieh, Cutler, Ho, Soiffer, Alyea & Lee, 2007)
It has also been attributed to higher healthcare costs, with increasing age is associated
with increasing costs, particularly in diseases prevalent in an older population. Other
studies have shown a gender difference in use of health care services, with females
having a higher utilization rate, and subsequently, higher cost. (Bertakis, Azari, Helms,
Callahan & Robbins, 2000)
Because this is a point in time sample, length of follow up variable is included in
the regression model to control for differences in patient follow up within the datamart.
Datamart differences in follow up may occur due to a variety of unrelated causes, for
example, death, loss of insurance, movement out of the region or a late occurrence in the
datamart. (Diehr, Yanez, Ash, Hornbrook & Lin, 1999) This is not a patient
characteristic but the variable is grouped as a predisposing characteristic in order to
control for the inherent differences in follow up present in the data. A relationship to the
need for resources group was explored but rejected due to the sample’s unknown
underlying differences in cause.
3.5.2.2. Patient Need.
Patient need level predictor variables include: (1) Treatment type (i.e., defined as
chemotherapy only or chemotherapy plus HCT; and (2). Episode severity level (i.e.,
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ranked from 1-4 with 1=low severity, 2=low/medium severity, 3=medium/high severity
and, 4=high severity).
Treatment of disease as well as disease severity level has the potential for
significant influence on both clinical outcome and cost and is well documented in the
literature. (Ashfaq, et.al, 2010, Cordonnier, et.al, 2005, Jacobs et.al, 2000, Yu, et.al,
2006) Treatment type will be defined as chemotherapy plus allogeneic and autologous
HCT or chemotherapy only. Severity is calculated per episode of treatment and utilizes
the patient’s comorbidities, prior healthcare use and prior types of services known in the
datamart. Calculations for severity level are provided in Appendix E.
3.5.2.3. Enabling resources
Enabling resources predictor variables include: (1) Patient county percent under
poverty (i.e., defined by the ZIP code of patient’s County and the corresponding U.S.
census reported % of residents from that county with income below poverty line and the
US census reported % below poverty line); (2) Payer type (i.e., defined by public payer or
private payer); (3) Provider type (i.e., defined by academic medical center or nonacademic medical center); and (5) Provider percent under poverty (i.e., defined by the
ZIP code of provider location and the corresponding U.S. census reported % below
poverty line).
The percent under poverty variable is used to assess individual level
socioeconomic effects. Clegg and colleagues reported a higher rate of late-stage cancer
diagnoses with lower socioeconomic status (Clegg, et.al, 2009). In 2009 study of HCT
outcomes, Baker and colleagues found low income patients , i.e. <$36,400, had lower

37

probability of overall survival and higher probability of treatment related mortality when
compared to higher income patients , i.e >$56,000, (Baker, Davies, Majhail, Hassebroek,
Klein, Ballen, Bigelow, Frangoul, Hardy, Bredeson, Dehn, Friedman, Hahn, Hale,
Lazarus, LeMaistre, Lobreiza, Maharaj, McCarthy, Setterholm, Spellman, Trigg,
Maziarz, Switzer, Lee, Rizzo, 2009). While Geronimus and Bound state that U.S.
census-based aggregate variables are not appropriate proxies for individual
socioeconomic status, Krieger and colleagues conclude that they are meaningful
measurements of area-based socioeconomics (Geonimus and Bound, 1998; Krieger, et.al,
2005). The percentage of persons living below the U.S. poverty line variable was
identified as meeting the criteria for as a valid and useful socioeconomic measurement.
In this study, all socioeconomic measures are area-based.
In prior behavioral health studies, payer type has been shown to impact cost
through differences in hospital length of stay. (Sclar, et.al, 2008) Because HCT is
generally reimbursed as a bundled payment by insurance companies, public versus
private sources of reimbursement may have an impact on initial treatment cost and may
impact treatment costs over time. Meropol and colleagues discuss the payer’s role in
reducing health care expenditures and the need to use evidence-based decision making
while determining cost efficiencies (Meropol, et.al, 2009). In 2009, Kantarjian and
O’Brien commented on the need to investigate the role of insurance policies in the young
adolescent age group, noting the lack of coverage lending to lack of care over prolonged
timeframes in this group (Kantarjian, et.al, 2009). Specific to HCT, Gajewski and
colleagues identify the need for consistent provider/payer dialogue to insure payer
support for and patient access to this treatment option (Gajewski, et.al, 2004).
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A 2003 article of hospital cost drivers, J. Hay identifies overall economic activity
of the community, price-level variation, hospital technology, hospital market and
healthcare labor force as some of the factors associated with inpatient cost growth. In
this study, provider type is defined as academic medical center versus not academic
medical center because of the expectation that academic medical centers will have a
different cost structure than community hospitals (Hayes, 2003). Yuan and colleagues
conclude that while teaching not-for-profit hospitals had better clinical performance than
other hospitals, they also had significantly longer length of stay (Yuan, Cooper,
Einstadter, Cebul & Rimm, 2000).
Provider ZIP code and % below poverty line is included to assess a community
level geographic and socioeconomic effect. Anderson’s behavioral model would predict
a community socioeconomic influence on the cost outcome due to access to higher levels
and quantity of health care services in more affluent socioeconomic locations. The
community SES measurement is based upon the location of the provider, its reported US
census % of persons below the US poverty line. The provider location is determined by
the reported address of the provider in the WHIO database. The study variables are listed
in Table 3.4.
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Table 3.4 Description of Study Variables.
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3.6. Statistical Analyses.
Use of administrative data bases to assess questions relating to health care cost
can create data analysis challenges. Because these databases are created for
reimbursement rather than research, they generally have limited scope regarding detailed
patient demographics, disruption in coverage, clinical outcomes and generally contain
censored data.
In a 1999 article, Diehr describes methods of analysis for health care cost and
utilization (Diehr, et.al, 1999). Multivariate regression is often used to identify cost
predictors within groups. The authors discuss the one part model as most efficient when
attempting to understand the effect of covariates on total cost because it creates a single
regression coefficient for each variable and results are easily interpreted. The article
provides additional detail regarding skewed cost data, differences in types of cost,
adjusting for different lengths of follow up and, death and censoring. Barber and
Thompson in a 2004 article discuss the use of generalized linear models (GLM) for the
analyses of cost data rather than ordinary least squares (OLS) and identify the gamma,
log link model as providing the best result. They identify challenges inherent in the
analysis of cost data because of a typical skewed distribution and the need to use
estimates of mean costs. Dodd and colleagues compared different multivariable
regression models for analyzing cost data and found gamma with log link modeling
provided the best result (Dodd, Bassi, Bodger & Williamson, 2006) .
This study uses recommendations from these articles to fit the best method to the
sample in order to analyze the study specific aims. The final decision of the GLM
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gamma log link model was made after an initial review of the study data and assessment
of its fit with model assumptions. SAS 9.3 software is used to analyze the multivariate
regression models all tests will be considered significant at the 0.05 level.
3.7. Complexity of Cost Data Analyses.
Analysis of cost data is complex due to the tendency of being right-skewed with
long, right tails, due to; (1) The presence of large numbers of low cost events in addition
to a few very high cost events; (2) The lack of negative events; (3) The higher utilization
of services due to more severe diagnosis; (4) The high cost of certain types of treatment;
(5) Differences in follow up; and (6) Some patients utilize health services at a greater rate
and are responsible for a higher proportion of heath care cost (Dodd, Bassi, Bodger,
Williamson, 2006; Barber & Thompson, 2004; Basu & Manning, 2009; Lin, 2000).
Estimates that are meaningful and easy to interpret are preferred by decision
makers. In economic or policy evaluation they will often rely on the differences in mean
costs and whether the differences in the means between groups are statistically
significant. However, the use of arithmetic mean healthcare costs can be misleading due
to the underlying nature of the data. Highly skewed data will have medians that greatly
differ from the means. Barber and Thompson, 2004, describe the generalized linear
models (GLMs) as useful for regression of cost models due to their flexible methods for
the analysis of mean costs, the allowances for non-normal data distributions and the ease
of interpretation of the results.
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3.8. Generalized Linear Model (GLM).
Using Ordinary Least Squares (OLS) regression with cost data is problematic due
to the non-normality of the data’s distribution which can result in a bias that may predict
negative costs. The calculation of a log transformed outcome variable can solve the nonnormal distribution problem but provides a result that is difficult to interpret given that
log transformed OLS estimates are differences in the transformed log cost, an outcome
that is not of interest. Generalized Linear Models (GLM) have been recommended for
the analysis of cost data because they allow the advantages of a log link in the model but
the differences in the mean outcome is estimated directly and statistical inferences are
easier to interpret (Neal & Simons, 2007; Manning & Mullahy, 2001; Dodd, et.al, 2006;
Basu, 2005; Manning & Mullahy, 2002).
GLM’s are extensions of traditional linear models but characterize data through a
link function (g) and a distribution family (F). In a GLM the mean of the sample relates
to a linear predictor through a nonlinear link function and the criterion probability
distribution conforms to an exponential family of distributions. A GLM link function,
such as log, logit, identity and inverse, characterizes the relationship of the raw
untransformed criterion scale to the predictors, i.e. the relationship between the predictors
and the mean criterion response variable. The GLM family specifies the criterion
distribution that reflects the mean-variance relationship where:
Gaussian = constant variance
Poisson = variance is proportional to the mean
Gamma = variance is proportional to the square of the mean
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Inverse Gaussian or Wald = variance is proportional to the cube of the mean
GLM’s can have a variety of forms but the general form is:
g(µi) = xiβi + e, yi ~F,
where µi is the expected mean value from the model, βi, are the regression coefficients, e
is the error and F represents the models distribution function. The criterion variable (Yi)
is independent and has a probability distribution from an exponential family. GLM
accommodates skewed data through variance weighting of the criterion variable rather
than transformation. The variance of the criterion depends on the mean through a
variance function V:
var(Yi) = ϕV(ui)/wi,
where ϕ is a constant and w is a known weight for each observation. If the weight is
unknown, it is estimated. Fitted generalized linear models are summarized through
parameter estimates, standard errors, goodness-of-fit statistics, confidence intervals and
hypothesis tests (Basu, 2005; Manning & Mullahy, 2001).
3.8.1. GLM gamma log link model.
GLM’s fit the needs of health care cost analysis because of a focus on criterion
means and flexibility in the selection of the distribution family. Literature comparing the
best GLM for use in health economic analysis routinely selects the gamma log link model
as a candidate for providing the best fit for health care cost data. (Dodd et.al, 2006;
Barber & Thompson, 2004) The gamma model is generally used with continuous and

44

non-negative response variables and assumes the constant coefficient of variation that is
often found in cost data.
Log transformation can be sometimes used to normalize cost data. The GLM log
link model assumes:
ln(E(y/x)) = Xβ; the relationship of the predictors to the log of the estimated
criterion mean cost.
The gamma family of distribution assumes variance, V, is proportional to the
square of the mean, µ2:
V(µ) = µ2, or V(y/x)proportional to [E(y/x)]2, or
V[y/x] = α[E(y/x)]λ,
where α is the shape of the parameter and λ is the specific distribution model (family)
used in the GLM.
The λ gives the family distribution:
λ = 0 Gaussian
λ = 1 Poisson
λ = 2 Gamma
λ = 3 Inverse Gaussian or Wald
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The appropriate use of the gamma model in this study is tested through the
modified Park’s test for the variance of each cost outcome. (Manning & Mullahy, 2001)
The modified Park’s test is defined as:
ln(Yi – Ŷi) = λ0 + λ1ln(Ŷi) + ei,
where ln(Yi – Ŷi) is the natural log of the raw residuals squared, ln(Ŷi) is the natural log
of the predicted Yi, λ0 is a constant and λ1 is the coefficient that gives the family.
The final GLM gamma log link model can be represented as:
ln[E(Yi)] = β0+β1X1+β2X2+ β3X3+…+βkXk; or
E(Yi) = exp(β0+β1X1+β2X2+ β3X3+…+βkXk),
where Yi is the criterion variable, E(Yi) is the expected value of the criterion variable, Xk
are the predictor variables and βk are the estimated coefficients. Maximum likelihood
estimation is used to calculate the parameters (β) of the model. The appropriate use of
the log link in this study is assessed through the distribution curves of the raw scale
variables, their residuals and the log scale variables and residuals.
3.8.2. Interpretation of the GLM gamma log link model.
In a GLM gamma log link model the relationship between the mean of the
criterion variable (Yi) and the predictor is defined as:
ln[E(Yi)] = β0+β1X1+β2X2+ β3X3+…+βkXk; or
E(Yi) = exp(β0+β1X1+β2X2+ β3X3+…+βkXk);
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where a change in the criterion variable is considered to be proportional to a change in
the predictor variable. Interpretations can be described as:
A 1 unit change in X1 would change the mean of Yi by a factor of exp(β1) or eβ1 or
changing X2 from 0 to 1 would change the mean of Yi by a factor of exp(β2) or
eβ2.
The model does not hold the other variables fixed and variable changes adjust for the
contributions of all other variables in the model.
In this study,
eβ >1 when β>0 and indicates increasing cost,
eβ <1 when β<0 and indicates decreasing cost and,
eβ =1 when β=0 and indicates no change in cost
The hypothesis being tested is:
H0: eβ =1
H1: eβ ≠1,
and tested with a Wald chi-squared statistic at α=0.05 level of significance.
3.9. Study Regression Models.
Two types of regression models will be tests: (1) An overall predictive model of
study variables; and (2) A hierarchical model.
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1. Predictive model of study variables:
1.

YTotalcost=β0+ β1length of follow up+β2age+β3gender+ β4treatmenttype +
β5severity + β6cty%bp + β7payertype + β8providertype + β9pro%bp + e

2.

YAncillarycost= β0+ β1length of follow up+β2age+β3gender+ β4treatmenttype +
β5severity + β6cty%bp + β7payertype + β8providertype + β9pro%bp + e

3.

YInpatientcost= β0+ β1length of follow up+β2age+β3gender+ β4treatmenttype +
β5severity + β6cty%bp + β7payertype + β8providertype + β9pro%bp + e

4.

YOutpatientcost= β0+ β1length of follow up+β2age+β3gender+ β4treatmenttype +
β5severity + β6cty%bp + β7payertype + β8providertype + β9pro%bp + e

5.

YPharmacycost= β0+ β1length of follow up+β2age+β3gender+ β4treatmenttype +
β5severity + β6cty%bp + β7payertype + β8providertype + β9pro%bp + e

6.

YProfessionalcost= β0+ β1length of follow up+β2age+β3gender+ β4treatmenttype +
β5severity + β6cty%bp + β7payertype + β8providertype + β9pro%bp + e

2. A two-step hierarchical regression model will test the effect of community and patient
enabling variables above and beyond the effect of patient predisposing characteristics and
need variables.
Hierarchical entry 1: Cost ~ length of follow up, age, gender, treatment type, severity.
Hierarchical entry 2: Cost ~ length of follow up, age, gender, treatment type, severity,
cty%belowpoverty, payer type, provider type, pro%belowpoverty.
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3.10. Study Power and Sample Size.
In the 4th edition of Using Multivariate Statistics, Tabachnick and Fidell advise to
attain the best result through the use of the fewest variables (Tabachnick and Fidell,
2001). Their list of consideration for variable use include cost, availability, meaning and
theoretical relationships. This study primarily relies on theoretical relationships
identified in prior research to select the variables. Given the economic perspective of the
study and the expected small sample size due to the rarity of the disease, the number of
variables identified for the analysis has been kept to a minimum.
An online sample size and power calculator was used and a calculated sample size
of 113 was identified as necessary to provide power of 0.80, assuming an alpha of .05,
anticipated effect of 0.15 (medium effect, Cohen, 1982).
(http://danielsoper.com/statcalc3/calc.aspx?id=1)
Multivariate regression also requires that the ratio of the number of subjects to
predictor variable to be substantial enough for the solution to be meaningful. Again,
Tabachnick and Fidell provide a simple rule of thumb equation: N ≥ 50 + 8m, where
m=the number of independent variables. In this study the number of independent
variables, m=9, resulting also in N ≥ 122 and expected power to be > 80% (Tabachnick
and Fidell, 2001).
The initial study dataset of identified an overall sample of 837 patients; however,
due to more limited availability of provider data, the analysis sample reduced to 638. In
addition, each cost criterion analysis utilizes only the data, and a corresponding sample
size, associated with that stated cost. All sample sizes were reviewed and determined to
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be greater than the minimum required N ≥ 122; sufficient to meet the requirement for
>80% power for the analysis. (Table 3.5)
Table 3.5. Sample Size by Cost Criterion.
Criterion variable
Total

Sample size
638

Ancillary

138

Inpatient

201

Outpatient

497

Pharmacy

325

Professional

618

3.11. Study Sample Flow Charts.
The initial sample of 837 eligible patient records from the WHIO data mart is
described in chapter 3 and is depicted in Figure 3.1. The sample size available for
statistical analysis was dependent upon the number of patient records that were present
within each cost criterion and is subsequently different for each. Power was assessed for
all samples and was found to meet the minimum requirement of 80%. Statistical analysis
with Generalized Linear Modeling was performed for each cost criterion. Hierarchical
modeling of patient and community enabling variables over and above patient
predisposing and need variables was performed for the total cost criterion only.
Figures 3.3-3.8 depict the selection flow charts for each cost. The total cost
sample (Figure 3.3) loses only those patients where provider data was unavailable and
includes the largest sample of 638. The professional cost sample of 618 (Figure 3.8), the

50

outpatient cost sample of 497, (Figure 3.6), the pharmacy cost sample of 325 (Figure 3.7)
and the inpatient cost sample of 201, (Figure3.5) solidly meet the minimum sample size
power requirements. The ancillary cost sample, (Figure 3.4) has the smallest group of
138.
Figure 3.3.Total Cost Sample Flow Chart.
Patients included in WHIO data mart, 4/1/2009-6/30/2011
N=3,864,345
Exclude DRG’s other than 200.xx-208.xx
N=3,851,841
Patients with a diagnosis of leukemia or lymphoma, (DRG 204-205)
N=12,504
Exclude patients with non-acute diagnosis
N=11,670
Patients with a diagnosis of acute leukemia
N=837
Exclude patients without county zip code
data, N=1
Patients with patient variable data, N=836
Exclude patients without provider data,
N=198
Total cost sample: Patients with patient and provider variable data,
N=638
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Figure 3.4.Ancillary Cost Sample Flow Chart.
Patients included in WHIO data mart, 4/1/2009-6/30/2011
N=3,864,345
Exclude DRG’s other than 200.xx-208.xx
N=3,851,841
Patients with a diagnosis of leukemia or lymphoma, (DRG 204-205)
N=12,504
Exclude patients with non-acute diagnosis
N=11,670
Patients with a diagnosis of acute leukemia
N=837
Exclude patients without county zip code
data, N=1
Patients with patient variable data, N=836
Exclude patients without provider data,
N=198
Total cost sample: patients with patient and provider variable data,
N=638
Exclude patients without ancillary cost
data, N=500
Ancillary cost sample, N=138
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Figure 3.5.Inpatient Cost Sample Flow Chart.
Patients included in WHIO data mart, 4/1/2009-6/30/2011
N=3,864,345
Exclude DRG’s other than 200.xx-208.xx
N=3,851,841
Patients with a diagnosis of leukemia or lymphoma, (DRG 204-205)
N=12,504
Exclude patients with non-acute diagnosis
N=11,670
Patients with a diagnosis of acute leukemia
N=837
Exclude patients without county zip code
data, N=1
Patients with patient variable data, N=836
Exclude patients without provider data,
N=198
Total cost sample: patients with patient and provider variable data,
N=638
Exclude patients without inpatient cost
data, N=437
Inpatient cost sample, N=201
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Figure 3.6.Outpatient Cost Sample Flow Chart.
Patients included in WHIO data mart, 4/1/2009-6/30/2011
N=3,864,345
Exclude DRG’s other than 200.xx-208.xx
N=3,851,841
Patients with a diagnosis of leukemia or lymphoma, (DRG 204-205)
N=12,504
Exclude patients with non-acute diagnosis
N=11,670
Patients with a diagnosis of acute leukemia
N=837
Exclude patients without county zip code
data, N=1
Patients with patient variable data, N=836
Exclude patients without provider data,
N=198
Total cost sample: patients with patient and provider variable data,
N=638
Exclude patients without outpatient cost
data, N=141
Outpatient cost sample, N=497
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Figure 3.7.Pharmacy Cost Sample Flow Chart.
Patients included in WHIO data mart, 4/1/2009-6/30/2011
N=3,864,345
Exclude DRG’s other than 200.xx-208.xx
N=3,851,841
Patients with a diagnosis of leukemia or lymphoma, (DRG 204-205)
N=12,504
Exclude patients with non-acute diagnosis
N=11,670
Patients with a diagnosis of acute leukemia
N=837
Exclude patients without county zip code
data, N=1
Patients with patient variable data, N=836
Exclude patients without provider data,
N=198
Total cost sample: patients with patient and provider variable data,
N=638
Exclude patients without pharmacy cost
data, N=313
Pharmacy cost sample, N=325
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Figure 3.8.Professional Cost Sample Flow Chart.
Patients included in WHIO data mart, 4/1/2009-6/30/2011
N=3,864,345
Exclude DRG’s other than 200.xx-208.xx
N=3,851,841
Patients with a diagnosis of leukemia or lymphoma, (DRG 204-205)
N=12,504
Exclude patients with non-acute diagnosis
N=11,670
Patients with a diagnosis of acute leukemia
N=837
Exclude patients without county zip code
data, N=1
Patients with patient variable data, N=836
Exclude patients without provider data,
N=198
Total cost sample: patients with patient and provider variable data,
N=638
Exclude patients without professional cost
data, N=20
Professional cost sample, N=618

3.12. Model Selection With Study Data.
An assessment of the study data for use with a GLM gamma log link model was
handled in two ways: (1) Visual inspection of both raw scale and residual scale data for
use of the log link; and (2) The modified Park’s test to identify the family. Prior cost
research was also used to guide the decision of the best choice of model.
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3.12.1. Distribution of criterion variables.
Graphical representation of the distribution of each criterion variable, for billed
cost and standard cost data, are presented in Figures 3.9-3.20. The distribution of the raw
scale, log raw scale, residual and log residual is provided. In each of the distributions, the
raw scale and residual scale distributions indicate non-normal, positively skewed
distributions that may display high kurtosis. Each of the variables maintained a
consistent distribution when comparing billed cost data to standard cost data. When
transformed to the log scale, some variables displayed a more normal distribution when
compare to others; inpatient cost (Figure 3.13-3.14) versus pharmacy cost (Figure 3.173.18). In general, transformation to the log scale resulted in a closer to normal
distribution and provides support for the use of the log link method.
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Figure 3.9. Distribution of Total Billed Cost.
Distribution of totla billed cost

Distribution of log total billed cost

Distribution of total billed cost residual

Distribution of log total billed cost residual
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Figure 3.10. Distribution of Total Standard Cost.

Distribution of total standard cost

Distribution of log total standard cost

Distribution of total standard cost residual

Distribution of log total standard cost residual
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Figure 3.11 Distribution of Ancillary Billed Cost.

Distribution of ancillary billed cost

Distribution of log ancillary billed cost

Distribution ancillary billed cost residual

Distribution of log ancillary billed cost residual
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Figure 3.12. Distribution of Ancillary Standard Cost.

Distribution of ancillary standard cost

Distribution of log ancillary standard cost

Distribution of ancillary standard cost residual

Distribution of log ancillary std cost residual
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Figure 3.13. Distribution of Inpatient Billed Cost.

Distribution of inpatient billed cost

Distribution of log inpatient billed cost

Distribution of inpatient billed cost residual

Distribution of log inpatient billed cost residual
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Figure 3.14.Distribution of Inpatient Standard Cost.

Distribution of inpatient standard cost

Distribution of log inpatient standard cost

Distribution of inpatient standard cost residual

Distribution of log inpatient std cost residual
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Figure 3.15. Distribution of Outpatient Billed Cost.

Distribution of outpatient billed cost

Distribution of log outpatient billed cost

Distribution of outpatient billed cost residual

Distribution of log outpatient billed cost residual
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Figure 3.16. Distribution of Outpatient Standard Cost.

Distribution of outpatient standard cost

Distribution of outpatient cost std residual

Distribution of log outpatient standard cost

Distribution of log outpatient std cost residual
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Figure 3.17. Distribution of Pharmacy Billed Cost.

Distribution of pharmacy billed cost

Distribution of log pharmacy billed cost

Distribution of pharmacy billed cost residual

Distribution of log pharmacy billed cost residual
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Figure 3.18. Distribution of Pharmacy Standard Cost.

Distribution of pharmacy standard cost

Distribution of log pharmacy standard cost

Distribution of pharmacy std cost residual

Distribution of log pharmacy std cost residual
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Figure 3.19. Distribution of Professional Billed Cost.

Distribution of professional billed cost

Distribution of log professional billed cost

Distribution of professional billed cost residual Distribution of log professional billed residual
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Figure 3.20. Distribution of Professional Standard Cost.

Distribution of professional standard cost

Distribution of log professional standard cost

Distribution of professional std cost residual

Distribution of log professional std cost residual
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3.12.2. Results of the Modified Park’s Test for Family Distribution of
Criterion Variables.
Results from the modified Park’s test to determine the family distribution of the
criterion variables are presented in Table 3.6. The test results were somewhat
inconclusive, with a λ ranging between 1.2 for standard outpatient cost and 2.0 for billed
ancillary cost. With these results either a gamma distribution or a Poisson distribution
would seem to be the most appropriate choice. Prior health economics research
consistently selects the gamma family as the choice for cost data distributions. Given the
range of results and relying on the prior studies, this study will use the gamma family
model.
Table 3.6. Results of Modified Park’s Test.
Cost Outcome

λ

s.e.

95% CI

p-value

Billed
Standard

1.5
1.4

0.0698
0.0694

1.3 – 1.6
1.3 – 1.6

<0.0001
<0.0001

Billed
Standard

1.3
1.3

0.2044
0.8251

0.9 – 1.7
0.8 – 1.8

<0.0001
<0.0001

Billed
Standard

1.4
1.2

0.1087
0.1001

1.2 – 1.6
0.9 – 1.3

<0.0001
<0.0001

Billed
Standard

2.0
1.9

0.2707
0.2326

1.5 – 2.5
1.5 – 2.4

<0.0001
<0.0001

Billed
Standard

1.3
1.6

0.0869
0.1056

1.1 – 1.5
1.4 – 1.8

<0.0001
<0.0001

Billed
Standard

1.3
1.8

0.1399
0.1653

1.0 – 1.6
1.4 – 2.1

<0.0001
<0.0001

Total cost

Inpatient cost

Outpatient cost

Ancillary cost

Professional cost

Pharmacy cost
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3.13. Protection of Human Participants and the Health Insurance Portability and
Accountability Act
In accordance with the Health Insurance Portability and Accountability Act
(HIPPA) requirements, all patient identifiers were removed prior to receipt of study data.
According to Public Health Information regulations this is considered a limited data set
because of the presence of ZIP code data.
The University of Wisconsin-Milwaukee Institutional Review Board granted
Exempt Status under Category 4 as governed by 45 CFR 46.101 on April 13, 2012.
Appendix F contains a copy of the New Study-Notice of IRB Exempt Status letter.
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CHAPTER 4: Results
Results of the data analyses presented in this chapter are separated into three
sections: (1) Descriptive statistics of the analysis variables for cost criterions; (2) Results
of the predictive model by cost criterion and cost type; and (3) Results of the hierarchical
model of patient and community enabling resources over patient predisposing
characteristics and need for services.
4.1. Descriptive Statistics of Analysis Variables.
Predictor variable characteristics are presented for each criterion in Tables 4.14.6: Total cost (Table 4.1); Ancillary cost (Table 4.2); Inpatient cost (Table 4.3);
Outpatient cost (Table 4.4); Pharmacy cost (Table 4.5); and Professional cost (Table 4.6).
Descriptive statistics of each criterion variable are presented for the billed cost (Table
4.7) and the standard cost (Table 4.8).
4.1.1. Descriptive statistics of predictor variables
In the WHIO datamart, patient claims are associated with type of services
rendered. A patient may not have used all service types within the 24 month timeframe
of this study causing the sample sizes between the six cost criterions to vary as seen in
the chapter 3 flow charts. Predictor variable descriptive statistics show similarities
between the samples for age, gender, patient % under poverty, payer type and provider %
under poverty but do show some differences in the percentages of: (1) Treatment type,
where there was a slightly higher percentage of treatment with HCT in ancillary cost and
inpatient cost (11-12% versus 3-6% respectively); (2) Levels of severity, where total cost
and professional cost had a low to medium/low range of severity; inpatient cost,
outpatient cost and pharmacy cost showed higher levels of severity in the low/medium to
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high/medium range and; ancillary costs showed medium/high to high levels of severity
and; (3) The mean length of follow up for patients ranged from a low of 330 days in the
total cost to a high of 445 days in the pharmacy cost and may be attributed to the
differences in the sample size as well as differences in the complexity of the total cost
claim (comprised of many types of services) versus the single services of the other costs.
4.1.1.1. Total cost.
The predictor variables descriptive characteristics of total cost are presented in
Table 4.1. This sample contained 837 patients but was reduced to 638 patients due to the
limited amount of provider data. Mean age was 27 years with a range of 0-90 with
slightly more males (56%) present. Mean length of follow up in the datamart was 330
days with a range from 0-729. The mean of the patient socioeconomic measure county %
under poverty is 12.36 and ranged from 4.6% – 26%.

Most patients were treated with

chemotherapy only (97%) and had a severity score that was either low or medium/low
(64%). Payer types were fairly evenly distributed; 48% commercial versus 52% public.
Community providers exclusively treated 49% of patients, 27% were treated at least once
at an academic medical center and 24% of the providers were undetermined. The mean
of the provider socioeconomic variable % under poverty was 6.35% and ranged from
0.5% - 39.6%.
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Table 4.1. Descriptive Statistics of Predictor Variables for Total Cost.
Predisposing characteristic
Age, n
Mean ± s.d.
Median
Range
Gender, n (%)
Female
Male
Length of follow up, n
Mean ± s.d.
Median

837
27 ± 23.64
17.0
0-90
837
367 (44)
470 (56)
837
330 ± 265
363

Need
Treatment type, n (%)
Chemotherapy only
Chemotherapy and HCT

837
810 (97)
27 ( 3)

Severity, n (%)
Low
Low/medium
High/medium
High

837
95 (11)
445 (53)
152 (18)
145 (17)

Enabling resources
Patient county zip code % under poverty,
n
Mean ± s.d
Median
Range

837
12.36 ± 4.47
12.2
4.6 – 26.0

Payer type, n (%)
Commercial
Public

837
400 (48)
437 (52)

Provider type, n (%)
Community
Academic medical center
Not determined

837
410 (49)
228 (27)
199 (24)

Provider zip code % under poverty, n
Mean ± s.d.
Median
Range

638
6.35 ± 5.9
3.3
0.5-39.6
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4.1.1.2. Ancillary cost.
The predictor variables descriptive characteristics of ancillary cost are presented
in Table 4.2. This sample contained 164 patients but was reduced to 138 patients due to
the limited amount of provider data. Mean age is 28 years with a range of 0-88 and more
males (62%) were present. Mean length of follow up in the datamart was 439 days with a
range from 0-729. The mean of the patient socioeconomic measure county % under
poverty is 12.43% with a range of 4.6% – 20.1%.

Most patients were treated with

chemotherapy only (88%) and this sample had the highest severity scores of either
medium/high or high (61% combined). The majority of payer types are public (56%).
Community providers exclusively treated 45% of patients, 39% were treated at least once
at an academic medical center and 16% of the providers were undetermined. The mean
of the provider socioeconomic variable % under poverty was 5.97% and ranged from
1.10% - 39.6%.
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Table 4.2. Descriptive Statistics of Predictor Variables for Ancillary Cost.
Predisposing characteristics
Age, n
Mean ± s.d.
Median
Range
Gender, n (%)
Female
Male

164
28 ± 25
17
0 – 88
164
62 (38)
102 (62)

Length of follow up, days, n
Mean ± s.d.
Median
Range

164
439 ± 235
461
0 – 729

Need
Treatment type, n (%)
Chemotherapy only
Chemotherapy and HCT

164
145 (88)
19 (12)

Severity, n (%)
Low
Low/medium
High/medium
High
Enabling resources
Patient county zip code % under poverty,
n
Mean ± s.d
Median
Range

164
10 ( 6)
53 (33)
40 (24)
61 (37)
164
12.43 ± 4.44
12.20
4.60 – 20.10

Payer type, n (%)
Commercial
Public

164
72 (44)
92 (56)

Provider type, n (%)
Community
Academic medical center
Not determined

164
74 (45)
64 (39)
26 (16)

Provider zip code % under poverty, n
Mean ± s.d.
Median
Range

138
5.97 ± 5.39
3.55
1.10 – 39.60
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4.1.1.3. Inpatient cost.
The predictor variables descriptive characteristics of inpatient cost are presented
in Table 4.3. This sample contained 232 patients but was reduced to 201 patients due to
the limited amount of provider data. Mean age is 27 years with a range of 0-90 and a
higher percentage of males (66%) are present. Mean length of follow up in the datamart
was 420 days with a range from 0-729. The mean of the patient socioeconomic measure
county % under poverty is 11.98 and had a range of 4.6% – 20.1%. Most patients were
treated with chemotherapy only (89%) and had severity scores of either medium/low or
medium/high (63% combined).

The majority of payer types were public (56%).

Community providers exclusively treated 48% of patients, 39% were treated at least once
at an academic medical center and 13% of the providers were undetermined. The mean
of the provider socioeconomic variable % under poverty was 6.10% and ranged from
1.2% - 39.6%.
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Table 4.3. Descriptive Statistics of Predictor Variables for Inpatient Cost.
Predisposing characteristics
Age, n
Mean ± s.d.
Median
Range
Gender, n (%)
Female
Male

232
27 ± 25
16
0 – 90
232
79 (34)
153 (66)

Length of follow up, days, n
Mean ± s.d.
Median
Range

232
420 ± 243
449
0 - 729

Need
Treatment type, n (%)
Chemotherapy only
Chemotherapy and HCT

232
206 (89)
26 (11)

Severity, n (%)
Low
Low/medium
High/medium
High
Enabling resources
Patient county zip code % under poverty,
n
Mean ± s.d
Median
Range

232
19 (12)
92 (39)
60 (24)
61 (25)
232
11.98 ± 4.19
12.2
4.60 – 20.10

Payer type, n (%)
Commercial
Public

232
102 (44)
130 (56)

Provider type, n (%)
Community
Academic medical center
Not determined

232
111 (48)
90 (39)
31 (13)

Provider zip code % under poverty, n
Mean ± s.d.
Median
Range

201
6.10 ± 5.61
3.20
1.20 – 39.60
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4.1.1.4 Outpatient cost.
The predictor variables descriptive characteristics of outpatient cost are presented
in Table 4.4. This sample contains 639 patients but is reduced to 497 patients due to the
limited amount of provider data. Mean age is 27 years with a range of 0-90 and with
more males (57%) present. Mean length of follow up in the datamart was 388 days with
a range from 0-729. The mean of the patient socioeconomic measure county % under
poverty is 12.23% with a range of 4.6% – 21.1%.

Most patients were treated with

chemotherapy only (96%) and severity scores ranged from medium/low or medium/high
(74% combined). The majority of payer types were public (52%). Community providers
exclusively treated 47% of patients, 30% were treated at least once at an academic
medical center and 23% of the providers were undetermined. The mean of the provider
socioeconomic variable % under poverty was 6.41% and ranged from 0.5% - 39.6%.
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Table 4.4. Descriptive Statistics of Predictor Variables for Outpatient Cost.
Predisposing characteristics
Age, years, n
Mean ± s.d.
Median
Range
Gender, n (%)
Female
Male

639
27 ± 24
17
0 - 90
639
274 (43)
365 (57)

Length of follow up, days, n
Mean ± s.d.
Median
Range

639
388 ± 252
413
0 – 729

Need
Treatment type, n (%)
Chemotherapy only
Chemotherapy and HCT

639
612 (96)
27 ( 4)

Severity, n (%)
Low
Low/medium
High/medium
High

639
71 (11)
338 (53)
131 (21)
99 (15)

Enabling resources
Patient county zip code % under poverty,
n
Mean ± s.d
Median
Range

639
12.23 ± 4.47
12.20
4.60 – 21.10

Payer type, n (%)
Commercial
Public

639
309 (48)
330 (52)

Provider type, n (%)
Community
Academic medical center
Not determined

639
303 (47)
194 (30)
142 (23)

Provider zip code % under poverty, n
Mean ± s.d.
Median
Range

497
6.41 ± 5.95
3.20
0.50 – 39.60
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4.1.1.5. Pharmacy cost.
The predictor variables descriptive characteristics of pharmacy cost are presented
in Table 4.5. This sample contains 390 patients but is reduced to 325 patients due to the
limited amount of provider data. Mean age is 27 years with a range of 0-90 and has
slightly more males (59%) present. Mean length of follow up in the datamart was 445
days with a range from 0-729. The mean of the patient socioeconomic measure county %
under poverty of 12.4% and had a range of 4.6% – 20.1%. Most patients were treated
with chemotherapy only (94%) with slightly higher severity scores of either medium/low
or medium/high (69% combined). The majority of payer types were public (56%).
Community providers exclusively treated 47% of patients were treated, 36% were treated
at least once at an academic medical center and 17% of the providers were undetermined.
The mean of the provider socioeconomic variable % under poverty was 6.7% and ranged
from 1.1% - 39.6%.
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Table 4.5 Descriptive Statistics of Predictor Variables for Pharmacy Cost
Predisposing characteristics
Age, years, n
Mean ± s.d.
Median
Range
Gender, n (%)
Female
Male
Length of follow up, days, n
Mean ± s.d.
Median
Range

390
27 ± 25
16
0 – 90
390
158 (41)
232 (59)
390
445 ± 240
488
0 – 729

Need
Treatment type, n (%)
Chemotherapy only
Chemotherapy and HCT

390
365 (94)
25 ( 6)

Severity, n (%)
Low
Low/medium
High/medium
High

390
38 (10)
185 (47)
84 (22)
83 (21)

Enabling resources
Patient county zip code % under poverty,
n
Mean ± s.d
Median
Range

390
12.40 ± 4.28
12.20
4.60 – 20.10

Payer type, n (%)
Commercial
Public

390
173 (44)
217 (56)

Provider type, n (%)
Community
Academic medical center
Not determined

390
185 (47)
140 (36)
65 (17)

Provider zip code % under poverty, n
Mean ± s.d.
Median
Range

325
6.70 ± 5,73
4.30
1.10 – 39.60
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4.1.1.6. Professional cost.
The predictor variables descriptive characteristics of professional cost are
presented in Table 4.6. This sample contains 748 patients but is reduced to 618 patients
due to the limited amount of available provider data. Mean age is 27 years with a range
of 0-90 with slightly more males (56%) present. Mean length of follow up in the
datamart was 350 days with a range from 0-729. The mean of the patient socioeconomic
measure county % under poverty is 12.41% with a range of 4.6% - 26%. Most patients
were treated with chemotherapy only (97%) and had a severity score ranging from low to
low/medium (65% combined).

The majority of payer types were public (53%).

Community providers exclusively treated 52% of all patients, 31% were treated at least
once at an academic medical center and 17% of the providers were undetermined. The
mean of the provider socioeconomic variable % under poverty was 6.4% and ranged from
0.5% - 39.6%.
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Table 4.6. Descriptive Statistics of Predictor Variables for Professional Cost.
Predisposing characteristics
Age, years, n
Mean ± s.d.
Median
Range
Gender, n (%)
Female
Male

748
27 ± 23
17
0 – 90
748
329 (44)
419 (56)

Length of follow up, days, n
Mean ± s.d.
Median
Range

748
354 ± 261
375
0 – 729

Need
Treatment type, n (%)
Chemotherapy only
Chemotherapy and HCT

748
722 (97)
26 ( 3)

Severity, n (%)
Low
Low/medium
High/medium
High

748
84 (11)
405 (54)
138 (18)
121 (16)

Enabling resources
Patient county zip code % under poverty,
n
Mean ± s.d
Median
Range

747
12.41 ± 4.55
12.20
4.60 – 26.00

Payer type, n (%)
Commercial
Public

748
352 (47)
396 (53)

Provider type, n (%)
Community
Academic medical center
Not determined

748
390 (52)
228 (31)
130 (17)

Provider zip code % under poverty, n
Mean ± s.d.
Median
Range

618
6.44 ± 5.98
3.60
0.50 – 39.60
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4.1.2. Descriptive statistics of criterion variables.
This study uses six cost criterion variables: (1) Total cost; (2)
Ancillary cost; (3) Inpatient cost; (4) Outpatient cost; (5) Pharmacy cost; and (6)
Professional cost. Each cost criterion is analyzed by both billed cost, presented in Table
4.7 and standard cost, presented in Table 4.8.
4.1.2.1. Billed cost.
Billed cost criterion descriptive statistics are presented in Table 4.7. Mean billed
costs varied greatly between criterion variables with inpatient cost having the highest
mean cost of $15435 ± $221,790 with range $790-$1,671,326, followed by total cost
mean $86,309 ± $206,913 with range of $29-$1,866,606, the pharmacy cost mean
$25,108 ± $80,850 with range $1-$1,447,914, the outpatient cost mean $21,424 ±
$43,720 with range $29-$571,594, the professional cost mean $16,077 ± $80,85 with
range $38-$203,272 and the ancillary cost mean $4,101 ± $8,475 with range $7-$63,360.
The median and quartile range of the data additionally provides useful distribution
measures of each criterion variable and indicate the presence of extreme values at both
low and high data points. There were large differences in value between the medians and
the means however, the medians showed a similar trend when comparing between the
criterion variables with an inpatient median cost $71,277 with quartile range $2,116$187,595, a median total cost $6,034 with quartile range $1,198-$66,093, a median
pharmacy cost $6,716 with quartile range $647-$26,652, a median outpatient cost $4,972
with quartile range $1,280-$23,915, a median professional cost $2,451 with quartile
range of $676-$17,748 and a median ancillary cost $1,262 with quartile range $373$3,878.
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Table 4.7. Descriptive Statistics for Billed Cost.
Criterion
variable
($)

25%
quartile

75%
quartile

Mean

Median

S.D.

Range

Total cost

86,309

6,034

206,913

29 - 1,866,606

1,198

66,093

Ancillary
cost

4,101

1,262

8,475

7 – 63,360

373

3,878

Inpatient
cost

155,435

71,377

221,790

790 – 1,671,326

26,116

187,595

Outpatient
cost

21,424

4,972

43,720

29 – 571,594

1,280

23,915

Pharmacy
cost

25,108

6,716

80,850

1 – 1,447,914

647

26,652

Professional
cost

16,077

2,451

80,850

38 – 203,272

676

17,748

4.1.2.2. Standard cost.
The descriptive statistics of standard cost is presented in Table 4.8. The standard
costs are consistently lower in value for all criterion variables when compared to billed
cost. Taking the lower value into account, the standard costs follow the same general
trend as the billed cost with a high mean, large standard deviation and wide range of data.
The inpatient cost has the highest mean cost $80,786 ± $104,001 with range $2,680$836,656, followed by the total cost mean $43,379 ± $102,703 with range $10$1,229,960 , the pharmacy cost mean $17,078 ± $60,011 with range $1-$1,097,438, the
outpatient cost of $8,410 ± $17,589 with range $10-$227,957, the professional cost mean
$6,490 ± 11,378 with range $7-$80,867 and, the ancillary cost mean $4,123 ± 8,833 with
range $5-$64,248. The median, combined with the 25%-75% quartile range provide a
more comprehensive description of the data. Inpatient cost has the highest median cost
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$40,908 and a 25%-75% quartile range $16,855 - $108,750, followed by the median
pharmacy cost $5,070 with a 25% - 75% quartile range $483 - $17,434, the median total
cost $2,723 with a 25% - 75% quartile range $539 - $35,471, the median outpatient cost
$1,953 with a 25% - 75% quartile range $493 - $9,208, the median ancillary cost $1,230
with a 25% - 75% quartile range $296 - $3,248 and, the median professional cost $1,002
with a 25% - 75% quartile range $298 to $7448. The professional cost had the greatest
reduction in value because of the standardization of cost and resulted in the lowest
median cost. Standard ancillary cost moved from the lowest median in the billed cost to
the second lowest median in the standard cost. All other costs remained in the same high
to low position.
Table 4.8. Descriptive Statistics for Standard Cost.
Criterion
variable
($)

25%
quartile

75%
quartile

Mean

Median

S.D.

Range

Total cost

43,379

2,723

102,703

10 – 1,228,960

539

35,471

Ancillary
cost

4,123

1,230

8,834

5 – 64,248

296

3,248

Inpatient
cost

80,787

40,908

104,001

2,680 – 836,656

16,855

107,750

Outpatient
cost
Pharmacy
cost

8,410

1,953

17,590

10 – 227,957

493

9208

17,078

5,070

60,012

1 – 1,097,437

483

17,434

6,491

1,002

11,379

7 – 80,867

298

7,448

Professional
cost

4.2. Results of the Predictors of Cost Model.
Multivariate methods were used to model the cost criterion variables related to:
(1) Whether a patients predisposing characteristics (i.e., age, gender and length of follow
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up), their need for service factors (i.e., treatment type and episode severity) and the
patient and community enabling resources (i.e., patient county of residence % under
poverty, payer type, provider type and its location % under poverty) are predictive of
cost; and (2) An examination of the magnitude of predictor variable influence on cost
criterion variables. The underlying hypothesis is each predictor variable will have a
significant effect on the cost criterion with varying degrees of magnitude. Generalized
linear model (GLM) gamma log link models were run for each cost criterion and each
cost type, billed and standard. Significance is assessed at the p ≤ 0.05 level.
Analysis results of the full and reduced models are presented by cost criterion and
cost type. The exponential conditional mean is reported as the eβ coefficient and
represents the proportional change factor; a one unit change in the predictor variable will
result in a proportional change of eβ in the criterion variable. The full model included all
predictor variables and was run separately for total billed cost and total standard cost.
Reduced model variables were identified in the GLM through a Type 3 analysis which
used a chi-square test of the likelihood ratio with, α=0.05. A second GLM analysis was
run using only the variables that tested as significant. Results for both the full model and
reduced model variables are presented.
4.2.1. Total cost.
The estimated results for the total cost are presented in Table 4.9. The full model
predictor variable estimates resulting in a significant increase to total cost included: (1)
Gender, where male gender is 1.69 times total billed cost of female gender ([CI=1.292.2], p<.0001) and a 1.59 times total standard cost of female gender ([CI=1.22-2.09],
p=.0007) and; (2) Length of follow up, where a per day increase in length of follow up is
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1.001 times the total billed cost ([CI=1.001-1.002], p<.0001) and with the same result in
total standard cost.
The significant variable estimates that resulted in a reduction to the cost criterion
variables included; (1) Treatment type, where the cost of chemotherapy only treatment is
0.12 times the cost of chemotherapy and HCT treatment ([CI=0.06-0.22], p<.0001); (2)
Severity level, where cost for lower levels of severity resulted in a reduction in cost when
compared to higher levels of severity. Severity level 1, low level, was 0.36 times the cost
of severity level 4, high level, ([CI=0.21-0.006), p<.0001) for total billed cost and 0.35
times the cost of severity level 4 for total standard cost ([CI=0.21-0.59], p<.0001) and,
severity level 2, medium/low severity, was 0.39 times the cost of severity level 4 in total
billed cost ([CI=0.27- 1.08], p=<.0001) and 0.41 times the cost of severity level 4 in total
standard cost ([CI=0.28-0.6], p<.0001; (3) Age, where a one year increase in age was
0.99 times the cost of the prior year in total billed cost, ([CI=0.98-0.99], p=0.0002) and
was similar, 0.99 times, in total standard cost, ([CI=0.99-0.99], p=0.002) and; (4)
Provider type, where the cost of claims from a community provider was 0.77 times the
cost of claims from an academic provider in total billed cost ([CI=0.51-0.89], p=0.007)
and 0.67 times the cost from an academic provider in total standard cost ([CI=0.5-0.88],
p=0.006).
Variable estimate results not significant in the models include: (1) Patient county
% under poverty, where a 1% increase in the percentage under poverty rate was 0.99
times total billed cost when compared to lower % under poverty ([CI=0.97-1.02], p=0.79)
with a similar result in total standard cost, 0.99, ([CI=0.97-1.22], p=0.77); (2). Payer
type, where a commercial payer was 0.77 times the cost of a public payer in total billed
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cost ([CI=0.59-1.02], p=0.06) and .79 times the cost of a public payer in total standard
cost ([0.59-1.04], p=0.1); (3) Severity level 3, was 0.96 times the cost of severity level 4
in total billed cost ([CI=0.47-1.08], p=0.12) and 0.77 times the cost of severity level 4 in
total standard cost ([CI=0.5-1.18], p=0.24) and; (4) Provider % under poverty where a
1% increase in the % under poverty rate was 0.99 times the total billed cost of the lower
poverty rate ([CI=0.98-1.02], p=0.65) and 0.99 times the total standard cost of the lower
poverty rate ([CI=0.97-1.16], p=0.49).
In the reduced model, severity level 3 and 4 were combined. The variable
estimates that resulted in a significant increase to the cost criterion variables include: (1)
Gender, where the cost of total billed for males was 1.75 times the cost of females
([CI=1.36-2.27], p=<0.0001), and 1.66 times the cost of females in total standard
([CI=1.28-2.15], p=0.0001); and (2) Length of follow up, where a one day increase in the
length of follow up was 1.001 times the cost of the shorter timeframe in total billed cost
and total standard cost, ([CI=0.001-0.002, p<0.0001).
Costs were significantly reduced by: (1) Treatment type, where chemotherapy
only cost was 0.13 times the cost of chemotherapy and HCT in total billed cost
([CI=0.06-0.23, p<0.0001) and 0.14 times the cost of chemotherapy and HCT in total
standard cost ([CI=0.06-0.26], p<0.0001); (2) Severity level, where severity level 1 was
0.44 times the cost of severity levels 3 and 4 in total billed cost, ([CI=0.28-0.7],
p=0.0003) and 0.41 times the cost of severity levels 3 and 4 in total standard cost,
([CI=0.26-0.61], p=0.0002) and severity level 2 was 0.44 times the cost of severity levels
3 and 4 in total billed cost ([CI=0.33-0.58], p<0.0001), and 0.45 times the cost of severity
levels 3 and 4 in total standard cost ([CI=0.34-0.61], p<0.0001); (3) Community
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providers resulted in 0.73 times the cost of academic providers in total billed cost
([CI=0.57-0.96], p=0.02), and 0.71 times the cost of academic providers in total standard
cost ([CI=0.54-0.94], p=0.01); and (4) A per year increase in age had 0.98 times the cost
of the prior year in total billed cost ([CI=0.98-0.99], p<0.0001) and 0.99 times the cost of
the prior year in total standard cost (CI=0.98-0.99], p=0.0007).
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Table 4.9. Estimated Results for Total Cost.

1

Results in bold are significant in the model
Severity level 3 and 4 are combined
*
Significant at α=.05
2
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4.2.2. Ancillary cost.
The estimated results for the ancillary cost are presented in Table 4.10. In the full
model, there were no significant variable estimates which resulted in an increase to the
cost criterion variable.
Variable estimates which significantly reduced cost included: (1) Level of
severity resulted in the largest cost decrease where, severity level 1 cost was 0.23 times
the cost of severity level 4 in ancillary billed cost ([CI=0.07-0.93), p=0.02), and 0.23
times the cost of severity level 4 in ancillary standard cost ([CI=.06-.97], p=0.03.
Severity level 2 was 0.32 times the cost of severity level 4 in ancillary billed cost
([CI=0.16-0.60], p=0.0005), and 0.27 times the cost of severity level 4 in ancillary
standard cost ([CI=0.13-0.52], p=0.0001). Severity level 3 was 0.30 times the cost of
severity level 4 in ancillary billed cost ([CI=0.16-0.57], p=0.0002) and 0.25 times the
cost of severity level 4 in ancillary standard cost ([CI=0.16-0.57], p=0.0002). All
severity levels were significant in the model but exhibited wide confidence intervals
making the estimate unreliable; (2) Provider type, where community providers ancillary
billed costs were 0.50 times the cost of academic providers ancillary billed cost,
([CI=0.29-0.87], p=0.02) and 0.48 times the cost of academic providers ancillary
standard cost, ([0.27-0.84], p=0.01); and (3) Age, where a per year increase in age
resulted in 0.98 times ancillary billed cost, ([CI=0.97-0.99], p=0.01) and with the same
result for ancillary standard cost.
Variable estimates that increased ancillary cost but were not significant in the
model include: (1) Payer type, where commercial payers were estimated as 1.60 times
the ancillary billed cost of public payers ([CI=.97-2.66], p=.06), and 1.21 times the
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ancillary standard cost of public payers ([CI=0.73-2.10], p=0.45); and (2) Patient county
% under poverty estimated 1.01 times ancillary billed cost per percentage increase in the
rate under poverty ([CI=0.96-1.06], p=0.66) and was 1.007 times ancillary standard cost
([CI=0.96-1.06], p=0.77). Variable estimates that reduced cost but were not significant in
the full model are: (1) Treatment type, where chemotherapy only treatment cost was 0.51
times the cost of chemotherapy and HCT in the ancillary billed cost ([CI=0.23-1.02],
p=0.07), and 0.54 times the cost of chemotherapy and HCT in the ancillary standard cost
([CI=0.25-1.07], p=0.10); (2) Gender, where cost for males was 0.85 times the cost for
females in ancillary billed cost, ([CI=0.50-1.44], p=0.57) and cost for males was 0.83
times the cost for females in ancillary standard cost, ([CI=0.47-1.43], p=0.52); (3)
Provider % under poverty, where with a 1% increase in the % under poverty ancillary
billed cost was 0.96 of the lower % under poverty, ([CI=0.92-1.01], p=0.08) and ancillary
standard cost was the same; and (4) Length of follow up, where with every 1 day increase
in ancillary billed cost was 0.99 times the prior day, ([0.97-0.99], p=0.58) and ancillary
standard cost was 0.99 times the prior day, ([0.97-1.00], p=0.72).
Three variable estimates entered the reduced model; age, severity and provider
type. Two of these variables significantly resulted in a cost reduction in the model: (1)
Severity levels had the largest effect where severity level 1 was 0.29 times the ancillary
billed cost of severity level 4 ([CI=0.10-1.01], p=0.05), and 0.24 times the ancillary
standard cost of severity level 4 ([CI=0.07-0.95], p=0.02), severity level 2 was 0.44 times
the ancillary billed cost of severity level 4 ([CI=0.24-0.81], p=0.008) and 0.34 times the
ancillary standard cost of severity level 4 ([CI=0.19-0.66], p=0.001) and severity level 3
was 0.42 times the ancillary billed cost of severity level 4 ([CI=0.22-0.81], p=0.008) and
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was 0.32 times the ancillary standard cost of severity level 4 (CI=0.17-0.61], p=0.0004);
and (2) Commercial providers had 0.45 times the ancillary billed cost of public providers
([CI=0.26-0.75], p=0.002) and 0.46 times the ancillary standard cost of public providers
([CI=0.26-0.79], p=0.005). Age was not significant in the reduced model.

Table 4.10. Estimated Results for Ancillary Cost.

1

Results in bold are significant in the model
Significant at α=.05

*
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4.2.3. Inpatient cost.
The estimated result for inpatient costs are presented in Table 4.11. In the full
model only gender, for billed cost only, significantly estimated an increase in the cost
criterion variable with male gender 1.4 times the inpatient billed cost compared to female
gender, ([CI=1.04-1.91], p=0.03.
Variable estimates that significantly reduced inpatient costs are: (1) Treatment
type, where chemotherapy only treatment is 0.25 times the inpatient billed cost of
treatment with both chemotherapy and HCT, ([CI=0.16-0.39], p<0.0001) and 0.28 times
the cost of inpatient standard cost of treatment with chemotherapy and HCT, ([CI=0.180.41], p<.0001); (2) Severity level, where Level 1 severity is 0.29 times the cost of level
4 severity of inpatient billed cost ([CI=0.17-0.53], p<.0001) and 0.26 times the cost of
level 4 severity of inpatient standard cost ([CI=0.18-0.53], p<.0001) and Level 2 severity
is 0.54 times the cost of level 4 severity of inpatient billed cost ([CI=0.38-0.78], p=0.001)
and 0.59 times the costs of level 4 severity of inpatient standard cost ([CI=0.42-0.83],
p=0.002); (3) Provider type, where costs of a community provider are 0.69 times the
inpatient billed costs of an academic provider, ([CI=0.5-0.94], p=0.02) and 0.71 times the
inpatient standard costs of an academic provider ([CI=0.53-0.94], p=0.02); (4) Age, a per
year increase in age resulted in 0.98 times the inpatient billed cost, ([CI=0.98-0.99],
p<.0001) and had the same result for inpatient standard cost; and (5) Length of follow up,
where the per day increase in length of follow up was 0.99 times inpatient billed cost,
([CI=0.99-0.99], p=0.03) and 0.99 times inpatient standard cost ([CI=0.99-1], p=0.02).
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Variable estimates that were not significant in the model include: (1) Gender
where the standard cost of males is 1.22 times the inpatient standard cost compared to
female gender, ([CI=0.93-1.61], p=0.15); (2) Payer type where a commercial payer is
0.86 times inpatient billed cost of a public payer, ([CI=0.64-1.17], p=0.35) and 0.86 times
inpatient standard cost of a public payer, ([CI=0.65-1.15], p=0.33) but is not significant
in both models; (3) Severity level 3 is 1.06 times the cost of level 4 severity in inpatient
billed cost, ([CI=0.72-1.55], p=0.75), and 1.18 times the cost of level 4 severity in
inpatient standard cost, ([CI=0.84-1.66], p=0.33); (4) Patient county % under poverty
where a percentile increase in the rate of county poverty is 1.01 times the inpatient billed
cost, ([CI=0.98-1.05], p=0.35) and is 1.01 times the cost of the inpatient standard cost,
([CI=0.99-1.04], p=0.32); and (5) Provider % under poverty where a 1% increase in the
rate of provider % under poverty is 0.99 times inpatient billed cost, ([CI=0.97-1.02],
p=0.89), and the same for inpatient standard cost.
In the reduced model, billed cost gender is the only variable estimate that
increased the cost criterion variables, where male gender was 1.41 times the cost of
female gender of inpatient billed cost, ([CI=1.05-1.89], p=0.02).
Variable estimates that significantly reduced inpatient cost included: (1)
Treatment type, where chemotherapy only treatment is 0.26 times the inpatient billed cost
of chemotherapy and HCT treatment, ([CI=0.16-0.40], p<.0001), and 0.30 times the
inpatient standard cost of chemotherapy and HCT treatment, ([CI=0.20-0.45], p<.0001);
(2) Severity level, where level 1 severity is 0.30 times the inpatient billed cost of level 4
severity, ([CI=0.17-0.55], p<.0001) and 0.28 times the inpatient standard cost of level 4
severity, ([CI=0.17-0.49], p<.0001) and level 2 severity is 0.53 times inpatient billed cost
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of level 4 severity, ([CI=0.39-0.73], p<.0001) and 0.55 times inpatient standard cost of
level 4 severity, ([CI=0.41-0.74], p<.0001); (3) Provider type, where a community
provider had 0.71 times the inpatient billed cost of an academic provider, ([CI=0.530.97], p=0.03) and 0.73 times the inpatient standard cost of an academic provider,
([CI=0.55-0.95], p=0.02); (3) Age, where a one year increase in age resulted in 0.98
times inpatient billed cost, ([CI=0.98-0.99], p<.0001), and had the same result for
inpatient standard cost; and (4) Length of follow up, where a one day increase in the
length of follow up resulted in 0.99 times inpatient billed cost, ([CI=0.99-1], p=0.04) and
0.99 times inpatient standard cost, ([CI=0.99-1], p=0.05), but was only just significant in
both models.
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Table 4.11. Estimated Results for Inpatient Cost.

1

Results in bold are significant in the model
Severity level 3 and 4 are combined
*
Significant at α=.05
2

4.2.4. Outpatient cost.
The estimated results for outpatient cost are presented in Table 4.12. In the full
model variable estimates that significantly increased outpatient cost included: (1)
Gender, where male gender is 1.31 times the outpatient billed cost compared to female
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gender, ([CI=1.05-1.66], p=0.02) and 1.30 times the outpatient standard cost compared to
female gender ([CI=1.04-1.63], p=0.02); and (2) Length of follow up, where a per day
increase in length of follow up was 1.001 times the outpatient billed cost, ([CI=1.0011.002], p=<.0001) with the same result in outpatient standard cost.
Variable estimates that significantly reduced outpatient cost included: (1)
Treatment type, where chemotherapy only treatment type is 0.20 times the outpatient
billed cost of chemotherapy and HCT, ([CI=0.12-0.33], p<.0001) and 0.19 times
outpatient standard cost of chemotherapy and HCT, ([CI=0.11-0.32], p<.0001); (2)
Severity level, where severity level 1 is 0.31 times outpatient billed cost of severity level
4, ([CI=0.19-0.50], p<.0001), and 0.32 times the outpatient standard cost of severity level
4, ([CI= 0.2-0.51], p<.0001), severity level 2 is 0.48 times outpatient billed cost of
severity level 4, ([CI=0.34-0.67], p<.0001) and 0.47 times outpatient standard cost of
severity level 4, ([CI=0.34-0.67], p<.0001, and severity level 3 is 0.63 times outpatient
billed cost of severity level 4, ([CI=0.44-0.91], p=0.02) and 0.64 times outpatient
standard cost of severity level 4 ([CI=0.44-0.92], p=0.02); (3) Provider type, where a
community provider is 0.55 times the outpatient billed cost of an academic provider,
([CI=0.44-0.71], p<.0001) and 0.56 times the outpatient standard cost of an academic
provider, ([CI=0.44-0.71], p<.0001); and (4) Age, where a one year increase in age is
0.99 times outpatient billed cost, ([CI=0.99-0.99], p=0.002) with the same result in
outpatient standard cost and; (5) Provider % under poverty where a 1% increase in the
rate of provider % under poverty is 0.97 times outpatient billed cost, ([CI=0.96-0.99],
p=0.02) with the same result in outpatient standard cost.
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Variable estimates that were not significant in the model include: (1) Payer type,
where a commercial payer is 0.95 times the outpatient billed cost of a public payer,
([CI=0.75-1.20], p=0.70) and 0.99 times the outpatient standard cost, ([CI=0.76-1.22],
p=0.76), but was not significant in both models; and (2) Patient county % under poverty
where, a 1% increase in the county % under poverty is 1.007 times outpatient billed cost,
([CI=0.98-1.03], p=0.51) and but is 0.99% ,a decrease, of outpatient standard cost,
([CI=0.98-1.03], p=0.53).
In the reduced model the two variables with estimates that contributed to an
increase in outpatient cost: (1) Gender, where male gender was 1.32 times the outpatient
billed cost of female gender, ([CI=1.05-1.64], p=0.02) and 1.30 times the outpatient
standard cost of female gender, ([CI=1.04-1.64], p=0.02); and (2) Length of follow up,
where a per day increase in length of follow up was 1.001 times the outpatient billed cost,
([CI=1.001-1.002], p<.0001) with the same result for outpatient standard cost.
The variable estimates that contributed to a decrease in outpatient cost included:
(1) Treatment type, where chemotherapy only treatment is 0.20 times the outpatient billed
cost of chemotherapy and HCT, ([CI=0.12-0.33], p<.0001) and 0.19 times the outpatient
standard cost of chemotherapy and HCT, ([CI=0.12-0.32], p<.0001); (2) Severity level,
where severity level 1 is 0.31 times the outpatient billed cost of severity level 4,
([CI=0.19-0.49], p<.0001) and 0.32 times the outpatient standard cost of severity level 4,
([CI=0.20-0.51], p<.0001), severity level 2 is 0.47 times the outpatient billed cost of
severity level 4, ([CI=0.34-0.66], p<.0001) with the same result in outpatient standard
cost and, severity level 3 is 0.63 times the outpatient billed cost of severity level 4,
([CI=0.43-0.90], p=0.01) and 0.64 times the outpatient standard cost of severity level 4,
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([CI=0.44-0.92], p=0.02); (3) Provider type, where a community provider is 0.56 times
the outpatient billed cost of an academic provider, ([CI=0.44-0.71], p<.0001) and 0.56
times the outpatient standard cost of an academic provider, ([CI=0.44-0.71], p<.0001)
and; (4) Provider % under poverty, where a 1% increase in the rate of % under poverty is
0.97 times the outpatient billed cost ([CI=0.96-0.99], p=0.02) with the same result in
outpatient standard cost.

102

Table 4.12. Estimated Results for Outpatient Cost.

1

Results in bold are significant in the model
Significant at α=.05

*

103

4.2.5. Pharmacy cost.
The estimated results for pharmacy costs are presented in Table 4.13.
The pharmacy cost models had the largest differences between billed cost and standard
cost results. In the full model, variable estimates that significantly increased pharmacy
costs included: (1) Gender, where billed cost only, male gender is 1.47 times pharmacy
cost compared to female gender, ([CI=1.03-2.09], p=0.03) and; (2) Length of follow up,
where a per day increase in length of follow up is 1.001 times pharmacy billed cost
([CI=1-1.002], p=0.002) and had the same result in pharmacy standard cost.
Variable estimates that significantly reduced pharmacy costs included: (1)
Severity level, where level 1 severity is 0.45 times the pharmacy billed cost of severity
level 4, ([CI=0.22-0.92], p=0.03) and 0.42 times the pharmacy standard cost of severity
level 4, ([CI=0.21-0.84], p=0.01), level 2 severity is 0.59 times the pharmacy billed cost
of severity level 4, ([CI=0.37-0.94], p=0.03) and 0.60 times the pharmacy standard cost
of severity level 4, ([CI=0.39-0.94], p=0.03) and severity level 3, standard cost only, is
0.60 times the pharmacy cost of severity level 4, ([CI=0.37-0.97], p=0.04) and; (2)
Provider type, where a community provider, in standard cost only, is 0.67 times the
pharmacy cost of an academic provider, ([CI=0.46-0.97], p=0.04); and (3) Provider %
under poverty, standard cost only, where a one percent increase in the rate of % under
poverty is 0.96 times the pharmacy standard cost, ([CI=0.93-0.99], p=0.01).
Variable estimates not significant in the full model include: (1) Gender, standard
cost only, where male gender is 1.33 times pharmacy cost compared to female gender,
([CI=0.95-1.87), p=0.09); (2) Severity level 3, billed cost only, is 0.66 times the
pharmacy cost of severity level 4, ([CI=0.40-1.1], p=0.11); (3) Treatment type, where
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chemotherapy only treatment is 0.91 times the pharmacy billed cost of chemotherapy and
HCT, ([CI=0.47-1.76], p=0.79) and 0.83 times the pharmacy standard cost, ([CI=0.441.55], p=0.5 6); (4) Payer type, where a commercial payer was 1.25 times the pharmacy
billed cost than a public payer, ([CI=0.87-1.80], p=0.22) and 1.39 times the pharmacy
standard cost, ([CI=0.99-1.07], p=0.06); (5) Patient county % under poverty, where a 1%
increase in patient county % under poverty is 1.02 times pharmacy billed cost, ([CI=0.981.06], p=0.3) and 1.02 times pharmacy standard cost, ([CI=0.99-1.07], p=0.16); (6)
Provider type, billed cost only, where a community provider is 0.73 times the pharmacy
billed cost of an academic provider, ([CI=0.50-1.08], p=0.12); and (7) Provider % under
poverty, billed cost only, where a one percentile increase in the rate of provider % under
poverty is 0.96 times the pharmacy billed cost, ([CI=0.94-1.05], p=0.05).
In the reduced pharmacy cost model, two variable estimates significantly
increased pharmacy cost: (1) Age, where a per year increase in age is 1.02 times the
pharmacy billed cost, ([CI=1.01-1.03], p=<.0001) and is 1.01 times pharmacy standard
cost, ([CI=1.01-1.02], p<.0001); and (2) Length of follow up, where a per day increase in
length of follow up is 1.002 times the pharmacy billed cost, ([CI=1.001-1.002], p<.0001)
up is <1.001 times pharmacy standard cost, ([CI=1-1.002], p=0.02).
Variable estimates that decreased pharmacy standard cost included: (1) Severity
level, standard cost only, where severity level 1 is 0.34 times the pharmacy standard cost
of severity level 4, ([CI=0.17-0.67], p=0.002), severity level 2 is 0.60 times the pharmacy
standard cost of severity level 4, (CI=0.39-0.93], p=0.02) and, severity level 3 is 0.59
times the pharmacy standard cost of severity level 4, ([CI=0.35-0.96], p=0.03); (2)
Provider type, standard cost only, where a community provider cost is 0.62 times the
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pharmacy standard cost of an academic provider, ([0.44-0.89], p=0.01); and (3) Provider
% under poverty, standard cost only, where a 1 % increase in the provider % under
poverty rate is 0.95 times the pharmacy standard cost, ([CI=0.93-0.98], p=0.002).
Gender is not significant in the reduced model.
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Table 4.13. Estimated Results for Pharmacy Cost.

1

Results in bold are significant in the model
Significant at α=.05

*
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4.2.6. Professional cost.
The estimated results for the professional cost are presented in Table 4.14. In the
full model only length of follow up increased professional costs where the per day
increase in length of follow up is 1.001 times professional billed cost, ([CI=1.001-1.002],
p<.0001), and 1.002 times professional standard cost, ([CI=1.002-1.003], p<.0001).
Variable estimates that significantly reduced professional costs included: (1)
Treatment type, where chemotherapy only treatment is 0.19 times the professional billed
cost of chemotherapy and HCT, ([CI=0.11-0.34], p<.0001) and 0.22 times the
professional standard cost of chemotherapy and HCT, ([CI=0.12-0.37]), p<.0001); (2)
Severity level, where severity level 1 is 0.44 times the professional billed cost of severity
level 4, ([CI=0.28-0.69], p=0.0003) and 0.48 times the professional standard cost of
severity level 4, ([CI=0.31-0.72], p=0.0006) and, severity level 2 is 0.44 times the
professional billed cost of severity level 4, ([CI=0.32-0.6], p<.0001) and is 0.46 times the
professional standard cost of severity level 4, ([CI=0.34-0.63], p<.0001); and (4) Age,
where a per year increase in age is 0.98 times the professional billed cost, ([CI=0.980.99], p<.0001), with the same result for professional standard cost.
Variable estimates that were not significant in the full model included: (1)
Gender, where male gender is 1.24 times the professional billed cost, ([CI=0.99-1.55]),
p=0.05) and 1.21 times professional standard cost, ([CI=0.98-1.5], p=0.08); (2) Severity
level 3 is 0.78 times the professional billed cost of severity level 4, ([CI=0.55-1.12],
p=0.19) and 0.82 times the professional standard cost of severity level 4, ([CI=0.58-1.17],
p=0.28); (3) Payer type, where a commercial payer is 0.95 times the professional billed
cost of a public payer, ([CI=0.75-1.19], p=0.67) and 0.93 times the professional standard
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cost of a public payer, ([CI=0.74-1.17], p=0.56); (4) Patient county % under poverty,
where a 1% increase in county % under poverty is 0.99 times professional billed cost,
([CI=0.97-1.02], p=0.94), and 0.99 times professional standard cost, ([CI=0.97-1.02],
p=0.66); (5) Provider type, where a community provider is 0.98 times professional billed
cost, ([CI=0.97-1.003], p=0.1) and 0.99 times professional standard cost, ([CI=0.971.008], p=0.31); and (6) Provider % under poverty, where a 1% increase in the provider
% under poverty rate is 0.98 times professional billed cost, ([CI=0.97-1.003], p=0.1) and
0.99 times professional standard cost, ([CI=0.97-1.008], p=0.31).
In the reduced model, the variable estimate that increased professional cost is
length of follow up, where a per day increase in the length of follow up is 1.002 times
professional billed cost, ([CI=1.002-1.003]), p<.0001) with the same result for
professional standard cost.
Variable estimates that resulted in a cost reduction were: (1) Treatment type,
where chemotherapy only treatment is 0.20 times the professional billed cost of
chemotherapy and HCT, ([CI=0.11-0.33], p<.0001) and 0.22 times the professional
standard cost of chemotherapy and HCT, ([CI=0.12-0.36], p<.0001); and (2) Severity
level, where severity level 1 is 0.45 times the professional billed cost of severity level 4,
([CI=0.32-0.65], p<.0001) and 0.47 times the professional standard cost of severity level
4, ([CI=0.34-0.67], p<.0001) and severity level 2 is 0.49 times the professional billed cost
of severity level 4, ([CI=0.39-0.62], p<.0001) and 0.51 times the professional standard
cost of severity level 4, ([CI=0.41-0.63], p<.0001).

109

Table 4.14. Estimated Results for Professional Cost.

1

Results in bold are significant in the model
Severity level 3 and 4 are combined
*
Significant at α=.05
2
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4.3. Results of the Hierarchical Model.
The hierarchical model (HM) analyzes the third specific aim of the study: to
investigate if patient and community enabling variables have added influence on cost
over and above patient predisposing characteristics and patient need for services. The
model was run using the total cost criterion data only and results are presented in Table
4.15. The hierarchical model was set up with three parts: (1) A model which included
only the patient predisposing characteristics of age, gender, length of follow up and the
need for services variables of treatment type and severity level and; (2) A model which
included all variables included in the study: the predisposing characteristics of age,
gender and length of follow up, the need for services variables of treatment type and
severity level and the patient and community enabling variables of payer type, county %
under poverty, provider type and provider % under poverty and; (3) A reduced model
which included only those variables that were significant in the full model.
The first model of patient predisposing characteristics and need for services
variables resulted in significant estimates for all variables with the exception of severity
level 3 and included: (1) A per year increase in age is estimated to be 0.99 times the total
billed and total standard cost outcome, ([CI=0.99-0.99]), p=0.0001) and ([CI=0.99-0.99],
p=0.001) respectively; (2) Male gender is estimated at 1.78 times the cost outcome of
female gender in billed cost and 1.68 times the cost outcome of female gender in standard
cost, (CI=1.37-2.29], p<.0001) and (CI=1.29-2.18], p<.0001). However, while there is a
significant p-value, the confidence intervals are wide and the estimate is not reliable; (3)
A per day increase in length of follow up in the datamart estimated a 1.001 increase in the
cost outcomes, ([CI=1-1.001], p<.0001) and ([CI=1.001-1.002]. p<.0001); (4)
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Chemotherapy only treatment was estimated to be 0.12 times the billed cost outcome of
chemotherapy and HCT and 0.13 times the standard cost outcome of chemotherapy and
HCT, ([CI=0.05-0.21], p<.0001) and (CI=0.06-0.23], p<.0001), indicating a large
difference between the treatment groups. Confidence intervals were in an acceptable
range; and (5) Severity levels 1 and 2 were significant in both the billed cost and standard
cost models. Level 1 estimates are 0.35 times the level 4 billed cost, ([CI=0.21-0.59],
p<.0001) and 0.34 times level 4 standard cost, ([CI=0.02-0.58], p<.0001). Level 2
estimates are 0.36 times level 4 billed cost, ([CI=0.25-0.51], p<.0001), and 0.38 times
standard cost, ([CI=0.26-0.54], p<.0001). Confidence intervals were in an acceptable
range. Level 3 severity was not significant in the model.
The full model added the patient and community enabling resources to the
analysis, patient county % under poverty, payer type, provider type and provider % under
poverty. Of these additional variables, only provider type was significant where a
community provider is estimated to be 0.68 times billed cost, ([CI=0.51-0.89], p=.007)
and 0.67 times standard cost, ([CI=0.50-0.88], p=0.006).
The reduced model incorporated all significant variables from the full model; age,
gender, length of follow up, treatment type, severity levels 1 and 2 and provider type and
had the same result as the total cost predictive variables model where: (1) Gender has a
large influence with male costs 1.75 times the billed cost of females ([CI=1.36-2.27],
p<.0001) and 1.66 times the standard cost of females ([CI=1.28-2.15), p=0.0001),
however the confidence intervals are wide and therefore the estimate may not be reliable;
(2) A per year increase in age is 0.98 times billed cost, ([CI=0.98-0.99], p<.0001) and
0.99 times standard cost, ([CI=0.98-0.99], p=0.0007); (3) A per day increase in the length
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of follow up increased billed cost by 1.001 times, ([CI-1.001-1.002], p<.0001) and had
the same result for the standard cost outcome, (4) Chemotherapy only is 0.13 times the
billed cost of chemotherapy and HCT, ([CI=0.06-0.23], p<.0001) and 0.14 times the
standard cost of chemotherapy and HCT, ([CI=0.06-0.26], p<.0001); and (5) Severity
levels 1 and 2 were significant in the model, however the variable continued to have a
problem with wide confidence intervals. Severity level 1 is 0.44 times the billed cost of
severity level 4, ([CI=0.28-0.70], p=0.0003) and 0.41 times the standard cost of severity
level 4, ([CI=0.26-0.62], p=0.0002). Severity level 2 is 0.44 times the severity level 4
billed cost outcome, ([CI=0.33-0.58], p<.0001) and 0.45 times the severity level 4
standard cost outcome and; (6) Provider type is the only community enabling resource
included in the reduced model. A community provider cost is 0.73 times the billed cost
([CI=0.57-0.9], p=0.02) and 0.71 times standard cost ([CI=0.54-0.95], p=0.01).
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Table 4.15. Estimated Results of the Hierarchical Model.

1

Results in bold are significant in the model

2

Severity level 3 and 4 are combined

*

Significant at α=.05
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4.4. Summary of Study Results.
A summary of the study results are provided for predictor variable characteristics,
criterion variable mean, the reduced models predictions and the hierarchical model
predictions.
4.4.1. Summary of predictor variable characteristics.
A summary of predictor variable characteristics for each cost criterion is
presented in Table 4.16.
Acute leukemia patient characteristics of the study sample are consistent with
what is reported nationally (http://seer.cancer.gov). Patient demographics were similar
for each criterion with a mean age of either 27 or 28 and a higher percentage of males,
ranging from 56%-66%, as expected from the higher rate of leukemia diagnoses in males.
This is similar to Surveillance Epidemiology and End Results (SEER) statistics showing
a higher percentage of men with acute leukemia diagnoses and a combination of a
younger ALL population and an older AML population.
The length of follow (LOF) up variable methodologically controls for systematic
differences in dates of service available in the data as recommended by Diehr (Diehr,
et.al, 1999). In this sample, mean LOF ranged from 330-445 days and had a range of 0729. Much of the date of service data indicated same day service, or a zero LOF. Total
and professional costs were larger samples and contain more of the zero LOF data
resulting in lower means, 330 days and 354 days respectively. Ongoing treatment is
more likely to be seen in ancillary cost, mean 439 day, inpatient cost, mean 420 days, and
outpatient cost, mean 388 days and would be expected to have a longer and more
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consistent LOF. The highest mean LOF present in pharmacy cost, mean 445 days,
reflects a higher level of ongoing pharmaceutical use.
Most of the patients were treated with chemotherapy only. Treatment type is
dominated by chemotherapy only, ranging from 94% - 97% in the total cost, outpatient
cost, pharmacy cost and professional cost. Ancillary cost and inpatient cost with slightly
lower percentiles of 88% and 89% respectively, reflect the higher use of services by the
HCT treated patients with males representing 63% of the HCT treatment type.
Level of severity is not similar between costs. Severity is measured by 4 levels
with1 as the lowest and 4 as the highest. Higher levels of severity of illness and related
hospitalization are reflected in the higher levels of severity in the hospital-based ancillary
cost and inpatient cost which show a higher percentage of high/medium to high levels of
severity, 38% and 51%. Total cost, outpatient cost, pharmacy cost and professional cost
show more low to low medium levels of severity, 57% to 65%.
Patient % under poverty had little variation between the mean percentages with a
limited range of 11.98% - 12.41%. The % under poverty rate was collected from U.S.
census data using the county zip code data from the WHIO datamart. Patient zip code
was available in the WHIO datamart at the county level only as part of data deidentification. Unfortunately, county level zip code data is very broad; limiting the
strength of the patient poverty measure.
There is a higher percentage of use of public payers in the acute leukemia
population. Payer type was similar in all costs and showed a higher percentile of public
payers compared to commercial payers, 52% to 56%; a result different from the U.S.
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census reported percentage of 31% of all Americans covered by public insurance in 2011
(www.census.gov/hhes).
The majority of acute leukemia patients receive care from a community provider
only. Provider type was similar in all costs with the majority of patients treated at a
community provider only, 45% - 52%. However of the 839 provider available, only 792
were identifiable, resulting in percentages of missing data ranging from 13% in inpatient
cost to 24% in total cost. Patient records with missing provider data were not used in
analysis. In addition, overall use of community providers is under represented due to
coding all claims for a patient who used an academic center as ‘academic’.
Providers that treat acute leukemia are located in areas with relatively low levels
of poverty. The provider % under poverty variable represents the U.S. census poverty
rate of the zip code of the provider and had a mean range of 5.97%-6.70%. Provider zip
code was obtained through the contact information listed in the WHIO datamart.
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Table 4.16. Summary of Predictor Variable Characteristics.
Variables
Predisposing
characteristics
Age, n
Mean
Gender, n (%)
Male
Length of follow up,
n
Mean
Need
Treatment type,
n (%)

Total
cost

Ancillary
cost

Inpatient
cost

Outpatient
cost

Pharmacy
cost

Professional
cost

837
27

164
28

232
27

639
27

390
27

748
27

837
470 (56)

164
102 (62)

232
153 (66)

639
365 (57)

390
232 (59)

748
419 (56)

837
330

164
439

232
420

639
388

390
445

748
354

837

164

232

639

390

748

Chemotherapy only

810 (97)

145 (88)

206 (89)

612 (96)

365 (94)

722 (97)

Chemotherapy and
HCT

27 ( 3)

19 (12)

26 (11)

27 ( 4)

25 ( 6)

26 ( 3)

Severity, n (%)
Low
Low/medium
High/medium
High
Enabling resources
Patient
% under poverty, n
Mean
Payer type,
n (%)
Commercial
Public
Provider type, n (%)
Community
Academic
medical center
Not determined
Provider
% under poverty, n
Mean

837
95 (11)
445 (53)
152 (18)
145 (17)

164
10 ( 6)
53 (33)
40 (24)
61 (37)

232
19 (12)
92 (39)
60 (24)
61 (25)

639
71 (11)
338 (53)
131 (21)
99 (15)

390
38 (10)
185 (47)
84 (22)
83 (21)

748
84 (11)
405 (54)
138 (18)
121 (16)

837
12.36

164
12.43

232
11.98

639
12.23

390
12.40

747
12.41

837
400 (48)
437 (52)

164
72 (44)
92 (56)

232
102 (44)
130 (56)

639
309 (48)
330 (52)

390
173 (44)
217 (56)

748
352 (47)
396 (53)

837
410 (49)
228 (27)

164
74 (45)
64 (39)

232
111 (48)
90 (39)

639
303 (47)
194 (30)

390
185 (47)
140 (36)

618
390 (52)
228 (31)

199 (24)

26 (16)

31 (13)

142 (23)

65 (17)

130 (17)

638
6.35

138
5.97

201
6.10

497
6.41

325
6.70

618
6.44
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4.4.2. Summary of criterion variable means.
A summary of the mean of each criterion variable by cost type is presented in
Table 4.17. Both types of cost, billed and standard, are analyzed to determine if their
model results are consistent.
Billed costs to patients do not reflect actual costs of service and are, with the
exception of ancillary cost, highly inflated. Average standard total cost is 50% less than
billed total cost with a mean of $43,379 versus $86,309, and represents a reduction
between the charges to the patient versus a valuation of actual cost of services. The
differences support concerns regarding the lack of financial transparency within the
health care sector.
Mean standard ancillary cost is equivalent to mean billed ancillary cost; $4,123
versus $4,101. Standard ancillary cost is based on relative value units, RVU’s, from the
Medicare fee schedule and in this sample the hospital facility charges are not higher than
the standard RVU rate.
Mean standard inpatient cost is 48% lower than mean billed inpatient cost;
$80,787 versus $155,435. Inpatient cost is standardized using a per diem cost, calculated
with the diagnosis-related group (DRG) and the length of stay, taking into account the
facility type and whether major surgery occurred. The differences between the mean
billed cost and mean standard cost identify differences in what is charged to the patient
versus an estimate of the actual cost of inpatient services.
Mean standard outpatient cost is 61% lower than mean billed outpatient cost;
$8,410 versus $21, 424. Outpatient standard cost uses a percentage of the billed amount
and is adjusted by a WHIO-specific conversion factor to approximate an allowed amount.
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Mean standard pharmacy costs are 29% lower than mean billed cost, $17,078
versus $24,108. Pharmacy costs are standardized using the average wholesale price
(AWP) for the National Drug Code (NDC), adjusted by the therapeutic category and
generic status.
Mean standard professional costs are 60% lower than mean billed costs; $6,491
versus $16,077. Professional cost also uses RVU’s to standardize cost and the variation
represents differences between what is charged to the patient and the RVU rate from the
Medicare fee schedule.
Table 4.17. Summary of Criterion Variable Means.
Criterion variable ($)
Total cost
Ancillary cost
Inpatient cost
Outpatient cost
Pharmacy cost
Professional cost

Mean billed cost

Mean standard cost

86,309
4,101
155,435
21,424
25,108
16,077

43,379
4,123
80,787
8,410
17,078
6,491

4.4.3. Summary of reduced model predictions.
A summary of the reduced model predictions for billed cost, Table 4.18, and
standard cost, Table 4.19, of each criterion variable is presented.
4.4.3.1. Billed cost.
Younger age is predictive of higher cost in the acute leukemia population; with
the exception of pharmacy cost and is the only variable included in every billed cost
reduced model. A per year increase in age generally resulted in a cost reduction by an
estimated 0.98-0.99 times the cost criterion, however pharmacy cost had an estimated
increase in cost of 1.02 times. In each of the reduced models, the confidence intervals are
small and, except for ancillary cost, p-values were significant. The result is opposite the
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documented increase in healthcare cost with increasing age as described in Seshamani
and Grey, and, Garrett and Martini reflecting the higher use and more aggressive
treatment of younger patients within the acute leukemia population. Pharmacy cost
follows the trend of higher cost associated with increasing age (Seshamani & Grey, 2004;
Garret & Martini, 2007). .
Male gender is significantly predictive of higher cost in total cost, inpatient cost,
and outpatient cost. Gender was not included in the ancillary cost and professional cost
reduced models and was not significant in the pharmacy cost reduced model. The gender
estimates in total cost, inpatient and outpatient cost models indicated a significantly
strong increase in cost for males ranging from 1.32 to 1.75 times female cost. While the
p-values were significant, the confidence intervals were wide for this variable making the
specific estimate not reliable. The result in this sample is opposite what is generally
reported in healthcare utilization where females have been shown to have a higher
utilization rate, and would be expected to have higher costs (Bertakis, et.al, 2000).
Length of follow up has a small but significant impact on the cost criterion. With
the exception of ancillary cost, length of follow up significantly entered every reduced
model and was significant in each of the models. In total, outpatient, pharmacy and
professional cost, length of follow up estimated a small per day increase in the costs with
estimates ranging from 1, no change, to <1.001. Inpatient cost showed a slight decline as
follow up increased with an estimate of 0.99 times a per day increase. Because this
variable controls for systematic differences in length of follow up in the sample, the
relative small effect indicates that these differences may not have a large influence on the
overall cost criterion but should not be ignored.
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Lower levels of severity show a large reduction in most costs. Severity level
entered every reduced model but pharmacy cost and is significant in every model except
for ancillary cost severity level 1. Lower levels of severity had a range of 0.3-0.53 times
the cost of severity level 4 and with p-values that are strong and similar between the
models. The confidence intervals for this variable are wide making the estimates
unreliable. However, while a specific rate may not be easily identified, it can be
concluded that lower levels of severity are significantly less costly than higher levels of
severity with between a 47% to 70% reduction in cost.
Patients treated with HCT experience significantly higher costs, up to 87% more
than patients treated with chemotherapy only. Treatment type estimates were significant
and included in each cost with the exception of ancillary cost and pharmacy cost. The
significant estimates predicted the chemotherapy only cost ranging from 0.13 times to
0.26 times the billed cost of patients treated with HCT. The variable estimate is strongly
significant in each model and had acceptable confidence intervals.
Community provider costs can be up to 55% lower than academic medical
centers; however the degree of reduction is dependent on the cost criterion. Except for
professional cost, provider type was included in all reduced models and was significant in
each. The estimated influence was mixed; it was strong in ancillary cost where a
community provider cost is 0.45 times that of an academic provider. However, its
confidence interval is wide and the specific estimate is not reliable. Total and outpatient
estimates of 0.73 and 0.71 respectively indicated a moderate influence; the confidence
intervals were better but still wide. The outpatient estimate of 0.97 was small, but the
confidence intervals were also small resulting in a more reliable estimate.
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Table 4.18. Summary of Estimated Reduced Model Results for Billed Cost.

4.4.3.2. Standard cost.
Younger age is predictive of higher cost in the acute leukemia population; with
the exception of pharmacy cost. This result in the standard cost type is the same as the
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result in the billed cost type. Age is the only predictor variable that is present in each of
the standard cost reduced models. In general, age estimated a reduction in standard cost
of 0.98-0.99 times per year increase in age, with the exception of pharmacy cost which
increased with age at an estimated 1.01 times per year. Age was not significant in the
final ancillary cost model. The confidence intervals in each of the significant models
were small and the p-values were strong.
Male gender is significantly predictive of higher cost in total cost, outpatient cost
and pharmacy cost. This result is different from the billed cost model in a few ways; the
variable did not enter the inpatient cost model as it did for billed cost, its estimates were
smaller for the models it did enter, and it was significant in pharmacy standard cost. The
significant estimates followed a similar trend as in billed cost with total costs resulting
in the highest estimate of a male gender cost being 1.66 times female cost, followed by
outpatient cost of 1.30 times and finally pharmacy cost of 1.002. However, only the
pharmacy cost had confidence intervals small enough to consider the result reliable.
Length of follow up has a small but significant impact on all cost criterions. This
result is similar to that of billed cost; length of follow up is present in all reduced models
with the exception of ancillary cost and was not significant in the inpatient cost reduced
model. In the standard total cost, outpatient cost, pharmacy cost and professional cost
reduced models LOF estimated a small per day increase in cost outcome ranging from
<1.001 – 1.002. The confidence intervals were small for this variable.
Lower levels of severity are predictive of lower cost. Severity level 1 and level 2
were significant in each of the models where both estimates resulted in a large reduction
in the standard cost when compared to the severity level 4 cost and ranged from 0.24
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times the level 4 cost in level 1 ancillary cost to 0.6 times the level 4 cost in level 2
pharmacy cost. While the p-values are strong, the confidence intervals are wide and the
specific estimates are not strongly reliable. Severity level 3 also estimated a reduction
from severity level 4 costs in the ancillary cost, outpatient cost and pharmacy cost models
and while p-values were significant, confidence intervals were, again, wide and the
estimates are unreliable. Overall the results are similar to those found in billed costs
except for a notable difference in pharmacy cost. In pharmacy billed cost, severity level
did not enter the reduced model; however, in pharmacy standard cost all levels of severity
entered the reduced model and all levels identified significantly lower costs compared to
level 4. It is important to clarify that pharmacy cost data does not include retail
pharmacy costs, only costs associated with a clinical or hospital provider. Differences
between billed costs and standard costs may be attributed to patient pharmacy charges not
reflecting hospital and clinic pharmacy cost efficiencies obtained through the use of
lower cost generics, bulk purchasing, other contractual reductions in price or eligibility
for the government’s 340B program, a program which reduces pharmacy cost to
providers who serve disadvantaged populations (www.nachc.org).
Patients treated with hematopoietic stem cell transplant (HCT) experience
significantly higher costs, up to 86% more, than patients treated with chemotherapy only.
Treatment type entered each of the reduced models with the exception of ancillary cost
and pharmacy cost. It estimated a large decrease in cost of treatment with chemotherapy
only with estimates ranging from 0.14 times in the total cost to 0.30 times in the inpatient
cost. Similar to billed cost, all reduced models were strongly significant for this variable
and confidence intervals are acceptable.
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Community provider costs can be up to 54% less than academic medical centers,
however the degree of reduction is dependent on the cost criterion. Provider type
significantly entered the models of total cost, ancillary cost, outpatient cost and pharmacy
cost with estimates reducing the cost criterion by 0.71 times, 0.46 times, 0.97 times and
0.62 times. The confidence interval for outpatient cost was small; however, confidence
intervals for the other estimates were wider making them less reliable. Still it may be
interpreted that in these costs, a community providers cost is significantly lower than an
academic medical center provider. This result is consistent with other studies that have
reported higher cost of academic medical centers, (Hays, 2003; Yuan, et.al, 2000).
Provider type results were different between standard cost and billed cost in two
instances: (1) A significant impact in inpatient billed cost but not in inpatient standard
cost; and (2) A significant impact in pharmacy standard cost but not in the pharmacy
billed cost. A possible explanation for the difference between inpatient cost types may be
that while the same services have the same actual cost in both types of providers there is
a significant difference between how the two provider types bill for those services.
Differences between pharmacy costs may be explained by academic medical centers
using newer, higher cost, non-generic drugs versus community providers or they may
reflect more community provider participation in the reduced cost 340B program (Hay,
2003; www.nachc.com). Interestingly, pharmacy billed charges to the patient were not
significantly different by provider type and may be attributed to providers who
experience cost efficiencies not passing on those reductions to the patient charges.
Providers located in areas with higher poverty rates have significantly lower
inpatient and pharmacy costs. Provider % under poverty significantly entered the reduced
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models with an inpatient estimate of 0.73 and a pharmacy estimate of 0.95. Both
estimates are significant, but the inpatient cost confidence interval is moderately wide
and makes the specific estimate less reliable. Inpatient standard cost is calculated using
a per diem cost, length of stay and the presence of surgery. This finding may reflect
disparities in clinical practice in areas of higher % under poverty levels and may be
associated with differences in diagnosis, treatment, effective use of evidence based
medicine and, ultimately, quality of care. The acute leukemia patient population is
regularly treated with chemotherapy and other high end pharmaceuticals. The estimated
lower pharmacy cost in higher poverty locations may be related to the higher use of
generics or lower cost pharmaceuticals in these locations as well as a higher rate of
participation in the 340B program which reduces pharmaceutical costs to providers
serving disadvantaged populations (www.nachc.com). From a different perspective, it
may relate to a higher use of more expensive, higher cost pharmaceuticals in wealthier
communities.
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Table 4.19. Summary of Estimated Reduced Model Results for Standard Cost.
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4.4.4. Summary of the hierarchical model results.
Results of the hierarchical model (HM) are presented in Section 4.3 and Table
4.15.
Patient predisposing characteristics and need for services have a significant
influence on the cost of care. In this acute leukemia sample, increasing age is associated
with decreasing cost, a finding different from what is generally observed, and men have
higher costs when compared to women, also a result different from the population norm
(Seshamani & Grey, 2004; Garret & Martini, 2007; Bertakis, et.al., 2007). The length of
follow up within the data set does have a slight influence on the cost outcome, and should
be kept in the model to control for differences. Type of treatment highly influences cost,
with patients who receive HCT having significantly higher costs compared to patients
receiving chemotherapy only. Lower severity of the disease episode reduces the cost
outcome when compared to higher levels of severity.
Only type of provider was significant when patient and community enabling
resources variables were added to the model. A community provider costs were less than
the costs of an academic medical center. Results are similar between billed cost and
standard cost. All other enabling resource variables did not enter the total cost reduced
model and did not significantly influence the cost outcome.
The reduced model of total cost resulted in the same set of variables of age,
gender, length of follow up, treatment type, severity level 1 and 2 and provider type and
all were significant in the final model. HM was performed for total cost only because of
this redundancy in the reduced model results. However, HM does identify the strong
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influence of patient predisposing characteristics and need for services variables on the
cost criterions.
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CHAPTER 5: Discussion
This study is a cross-sectional secondary analysis of WHIO insurance claims data
for patients diagnosed with acute leukemia. The primary objective was to investigate
how patient and community factors influence health care claims cost from the State of
Wisconsin. A secondary objective was to evaluate whether patient and community
enabling factors have added influence on cost over and above patient characteristics and
need factors. An underlying objective of the study was to assess the type of data available
in the WHIO datamart and its usefulness for cost research. This chapter will provide: (1)
An overview of the study findings; (2) Study limitations; and (3) Recommendations for
future research.
5.1. Discussion of Study Findings.
Anderson’s basic model of health care utilization suggests that certain patient and
community characteristics are considered to be predictive of a higher use of health care
services (Andersen, 1968). The model guides how to investigate the influence of a
limited set of administrative variables on cost. Because acute leukemia is a relatively
uncommon disease holds promise to have high treatment costs the use of an
administrative database is of interest because it is expected to contain a large enough
sample of patients for the analysis of costs. From the study results it can be concluded:
(1) Predisposing characteristics of acute leukemia patients may not follow the commonly
reported direction of cost where higher cost is associated with older age and female
gender. Instead their costs are expected to be higher in younger, male patients; (2) As
expected, the need for service variables of treatment type and severity level influence cost
and are significant cost drivers; (3) Community enabling resources of provider type and
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provider location influence cost where academic medical centers are associated with
higher cost and providers located in areas with higher poverty are associated with lower
costs; both raise questions of equity in treatment offered to patients dependent on where
they receive treatment; and (4) Costs related to different service types cannot be assumed
to follow similar predictive patterns and will subsequently have differences in
interpretation. Research involving cost estimation and cost effectiveness should clearly
identify the type of service costs being analyzed.
5.1.1. Influence of patient predisposing characteristics.
As expected, this study has confirmed that certain patient characteristics are
predictive of cost. However, their influence on cost in an acute leukemia population was
not always similar to what is more generally found. Prior research has shown that as the
age of the U.S. population increases, the utilization rate and cost of health care also
increases (Seshamani & Grey, 2004; Garret & Martini, 2007). As age increased in the
acute leukemia sample the cost criterion decreased in all but pharmacy cost. This may be
attributed to a number of factors including more aggressive and costly treatment of
younger patients as well as less treatment options and therefore lower cost for older
patients. Hematopoietic stem cell transplant (HCT) is not common in patients over 70
years of age and both HCT and chemotherapy treatment becomes increasingly less
aggressive in patients over the age of 60. Interestingly, Zweifel and colleagues argue that
age as a driver of higher cost becomes insignificant when proximity to death, and the
resulting costs, is controlled for. This study supports cost of treatment being the
important cost driver rather than age (Zweifel, Felder, Werblow, 2004).
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Bertakis identified a gender difference in the use of healthcare services with
women having a higher rate of use (Bertakis, et.al, 2000). However, in this study men
had higher costs; over 50% more in some instances. The percentage of males in the study
sample was comparable to the Surveillance Epidemiology and End Results (SEER)
reported diagnosis population for the acute leukemia’s; 56% in the study sample versus
SEER reported 58% in ALL and 53% in AML.
5.1.2. Influence of patient need for services.
The results of this study confirm the expected higher health care costs for acute
leukemia patients associated with their high need for health care services. A higher level
of severity, related to more comorbidity, would be expected to increase the cost of care
and this variable was significant in each cost service type. Treatment type was
significant in all models with the exception of ancillary cost and pharmacy cost and
represents a major driver of cost. Treatment with hematopoietic stem cell transplant
(HCT) significantly increases the cost of care in all other service types; total, inpatient,
outpatient and professional. It is not unexpected that HCT influences cost, however, the
strength of its influence, with costs up to 86% higher than chemotherapy only treatment
was more than expected. The result is consistent with HCT’s identification as the
procedure with the most rapidly increasing cost between 2004 and 2007 and it is assumed
that the cost will continue to increase over time (Stranges, et.al, 2009). HCT cost has
been reported in numerous articles with subjects ranging from cost effectiveness of
different treatment options to its overall cost of treatment (Majhail, et.al, 2009;
Westerman, et.al., 1996; Waters, et.al., 1998; Cordonnier, et.al., 2005; Lee et.al., 2000;
Lin et.al., 2010). Khera and colleagues provide a comparison of HCT economic studies
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and identify the need for high quality measures of cost and value-based assessments
(Khear, Zeliadt, & Lee, 2012). This study provides a quality measure of cost; the
challenge will be to link the cost to clinical outcome and to create a value measurement.
Given that HCT is intended to be a life-saving treatment, usually of last resort, a quality
adjusted life years (QALY) study could be designed to investigate the cost per year of life
saved. Advances in scientific knowledge have expanded its use to a variety of
hematologic diseases, disorders as well as patients. However, it’s extremely high cost
makes it vulnerable to cost containment processes. In order to insure that this type of
treatment is equitably offered based on clinical outcome rather than the ability to pay,
valued-based research (i.e. value=cost+outcome) needs to be used to support wellinformed policy decision making.
5.1.3. Influence of community enabling resources.
An important finding of this study is that the community enabling variables
provider type and provider location influence some costs. In Anderson’s model,
socioeconomics is considered a factor that may impact how patients use heath care
services where higher socioeconomic status is related to factors that support higher
utilization, (i.e. if a healthcare provider is located in the community, all services are
easily accessible, if there are preventive services, etc.). In this study, the rate of poverty
around the location of the provider is a socioeconomic measure of differences between
providers located in areas with higher poverty versus providers located in wealthier areas.
The provider % under poverty variable estimate was significant in both inpatient standard
cost and pharmacy standard cost and resulted in a cost reduction where lower costs were
associated with providers located in areas of higher levels of poverty.
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Inpatient costs are standardized using a per diem cost calculated with the factors
of; diagnosis related group (DRG), length of stay, facility type and presence of major
surgery. Provider percent under poverty uses the U.S. census defined % under poverty
rate identified through the zip code of the provider. Reduced costs in areas of higher
poverty would reflect a reduction in any one of the defined factors of; lower cost DRG’s,
shorter length of stays, lower cost facility types and less major surgery or some
combination. A study by Billings and colleagues identified higher hospitalization rates in
low-income areas due to less timely and effective outpatient care; however, this study
found the opposite result for inpatient cost (Billings, Zeitel, Lukomnik, Carey, Blank, &
Newman, 1993). Whereas it is not in the scope of this study to assess the type of health
care services provided at different provider locations, future work could investigate
possible differences in the types of services provided, the provider’s availability to offer
certain services, and whether access to needed health care services is compromised in low
income areas.
In the pharmacy cost sample lower standard cost is also associated with higher
levels of poverty of the provider’s location. Pharmacy costs are standardized using the
average wholesale price from the National Drug Code (NDC), adjusted by therapeutic
category and generic status. Pharmacy costs in this study did not include retail pharmacy
costs. Using the standardization definition, a reduction in pharmacy cost would be
associated with either different therapeutic categories, use of more generic statuses or
participation in the 340B Drug Pricing Program where drug manufacturers provide a
reduced 340B price for covered outpatient drugs to certain safety net providers who
participate in the program. Safety net providers include health centers receiving grant
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funding under Section 330 of the Public Health Service Act and similar centers. Most
providers in lower socioeconomic locations would be eligible for participation in this
program and the National Association of Community Health Centers (NACHC) report
that the program can help them save between 15%-60% on their prescription drug costs.
(www.nachc.com/client/documents). In this study, the lower pharmacy cost for providers
in poorer locations may be a reflection of participation in this program. Another
interpretation of the finding is that providers in poorer locations offer fewer therapeutics,
more generic drugs or some combination. A potential use of WHIO data could be an
assessment of differences in the type of services offered by provider location; the data
may support research related to the socioeconomic influence on availability of care and
access to care. Finally, it is concerning that the cost difference found in the pharmacy
standard cost model is not present in the billed cost model and it appears that lower costs
attained by the provider are not passed on to the consumer.
5.1.4. Variation in type of service cost estimators.
The study findings highlight the variation in predicted cost estimators between
type of service, (i.e., total, ancillary, inpatient, outpatient, pharmacy and professional),
resulting in sometimes significantly different interpretations. Overall, results vary in both
direction and degree of influence and are dependent on the type of services which creates
the cost. Only total cost and outpatient cost contained the same variables in the reduced
standard cost model with estimators that followed the same direction and with similar
influence. Significant variables in the total and outpatient cost samples relate to many
components of Anderson’s model with; the patient predisposing characteristic variables
age and gender, the patient need for services variables treatment type and severity level,
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and the community enabling resources variable provider type. All other costs identified a
mixed group of variables which significantly influenced the cost criterion. The ancillary
standard cost and professional standard cost reduced models resulted in the fewest
number of significant variables, but did not include the same significant variables in the
final models, creating differences in model interpretation. For example, treatment type is
significant in the professional cost sample, but not in the ancillary cost sample, and may
be related to a larger number of health care professionals involved in HCT treatment, a
higher cost of at least some of those professionals, as well as the longer treatment time.
Whereas provider type was significant in the ancillary cost sample, but not in the
professional cost sample, and estimated lower costs in community providers versus
academic providers. This finding is possibly related to differences in the facilities cost
and staff labor cost, an interpretation supported by Hay’s article of hospital cost drivers
(Hay, 2003). Pharmacy cost contained the largest number of significant variables in the
reduced model and resulted in variable estimates that did not always follow the same
direction of the other costs.
Overall, it can be concluded that there is inherent complexity in assessing cost
drivers that cannot be addressed through investigating total costs alone. All cost
research, whether it relates to cost effectiveness, estimation or value, should thoughtfully
determine what cost type is best for its design and then clearly define all costs that are
included.
A separate interest of this study was to investigate whether different cost types,
billed and standard, would have similar patterns in their results. This question is
considered important because of the difference in the cost perspective of the two; billed
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cost represents what is charged to the patient or consumer perceived cost and standard
cost is the expected actual cost of service or the hospital perceived cost. Whereas billed
cost and standard cost were similar in some service types there were large differences
present for both inpatient cost and pharmacy cost.
Because standard cost reduces variation caused by factors such as insurance
contractual differences and regional billing practices it makes it easier to interpret the
actual value of the cost result. This study’s findings defend standard cost as a more
meaningful research variable. Use of standard cost in research is discussed in the
literature which consistently identifies it as providing a valuation of actual cost and more
meaningful interpretation of findings (Finkler, et.al., 1982). However, differences
between billed and standard cost raise serious questions regarding the lack of
transparency in healthcare costs to the consumer. For example, lack of cost transparency
may result in an inflated patient perception of cost and interesting questions may relate
to; how the patient perceives cost and those perceptions behavioral impact on how they
obtain healthcare services, how patients perceive the accessibility of higher cost
providers, and ultimately the clinical outcomes of care they receive. Questions like these
have national healthcare political and policy implications. Finally, paid cost, a variable
not available for use in this study but is present in the WHIO database, could provide a
payer perspective of health care cost as well as relevant information regarding if and
when patients change payer type. This variable would define the amount actually paid by
insurance for services, and along with the billed and standard cost, would provide a more
complete picture of how costs operate within the healthcare sector.
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5.2. Study Limitations.
Limitations of this study include issues such as meaningfulness of data available
in administrative databases, disease sample size limitations, and generalizability of results
outside the State of Wisconsin. Research using the WHIO all payer claims data should be
designed to accommodate these inherent limitations. Administrative data will generally
restrict both the type and scope of research questions that can be addressed. Healthcare
claims data has limitations due to data censoring related to the both the amount of
available follow up and death, where time of death is unknown. Finally, data collection
issues outside of the researcher’s control, such as coding errors and diagnosis errors, may
impact the data. Limitations to the data include:
All payer claims databases are constructed for operational administration and
reimbursement of health care charges rather than research projects. The WHIO data does
not provide critical clinical outcomes which would allow the investigation of important
questions related to healthcare value and quality of life. Comorbidity data relates only to
that reported through insurance claims and may not be fully inclusive of other factors
impacting health.
About 6% of provider demographic information was not available in the datamart.
This represented either State of Wisconsin providers that were unidentifiable or out of
state providers. Lack of provider information reduced the size of the analysis sample in
all costs.
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Patient zip code data were only available on the county level, reducing its
specificity. The variable was not significant in any of the models, but may have been too
broad of a measure to identify differences.
Because the dataset contains only two years of insurance claims data it is not
possible to assess longitudinal cost results for this sample. Costs of care for these
diseases are expected to be high and a longer time frame would be of interest to assess
longer term trends in cost.
Given the limited patient demographic and clinical outcome information, there is
an increased risk of sample size bias due to factors that were unavailable, (i.e. patient
race). This may be particularly obvious for variables such as % under poverty, because of
its broad measure and provider type, which contained missing data.
Healthcare claims will contain censored data due to inherent differences in patient
follow up or death. While this study adjusted for censoring within the regression
equations, more robust statistical methods should be explored to better handle differences
in follow up. In addition, a future model may choose to define length of follow up as a
confounding variable rather than using the predisposing characteristic definition used in
this study. Finally, acquisition of survival data would need to be explored prior to an
expansion of the statistical method to better handle censoring due to death.
Study results do not reflect uninsured costs of treatment and are limited in
regional scope. This State of Wisconsin all payer claims dataset does not contain
information from insurance claims from outside the state nor does it provide uninsured
costs of treatment. In September, 2011, the U.S. census bureau estimated that 16.3% of

140

the U.S. population was uninsured in 2010 and Stranges and colleagues report
approximately 25% of hospital stays from 2004-2007 for HCT treatment were uninsured,
raising a question of whether the overall uninsured percentage in patients with an acute
leukemia diagnosis may be higher than that found in the general population (Stranges,
et.al, 2009). Finally, because this is a single State dataset, it may have limited
generalizability to populations outside of the State of Wisconsin given regional variations
in health care cost.
5.3. Recommendations for Future Research.
A number of future research opportunities result from this study and include
proposals to expand the current study dataset with increased years of data as well as
additional types of claims along with proposals for investigating the potential to link the
cost data to outcomes data. A discussion of each is provided.
In order to address questions of value in health care it is necessary that a study
include both cost and outcome. Linking cost data to outcomes data such as mortality,
comorbidity and quality of life would provide the necessary two components of the value
equation; cost and outcome. While the WHIO data provides a large amount of cost data,
it can only construct outcomes data as it relates to insurance claims; for example
comorbidities are used to determine severity level. However, because the calculated
severity level is restricted to insurance claims it does not capture all pertinent clinical
features of the patient. It will be important to explore avenues to obtain outcomes data
either through potential direct linkages to clinical datasets, such as State level mortality
data, or through possible statistical methods available to relate group cost outcomes to
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group clinical outcomes. An example would be to investigate a relationship between the
male gender cost outcomes to a male gender HCT survival outcome.
This study’s data is restricted to costs associated with an acute leukemia diagnosis
due to both data availability and dataset size. Expanding this diagnosis based dataset to a
dataset of all insurance claims for these patients would create a more complete record of
health care use. The acute leukemia population is expected to utilize health care
resources at a higher rate, costs associated with all claims would provide important
information about both the use of and cost of services not directly tied to the leukemia
diagnosis. It is important to note that the total amount of claims data for this group would
be large and would require a high level of technical resources to manage the dataset.
WHIO refreshes the datamart every six month and new patient records are added
or current patient records are extended. Adding future WHIO data to the study dataset as
it become available would enhance the current data and create the ability to design
longitudinal cost studies and creating a larger sample of HCT data. Because cost studies
of HCT are difficult due to small sample sizes, creating a dataset of HCT treatment cost
would allow investigations of not only longitudinal cost outcomes and cost effectiveness
analyses but would also provide support for cost comparison studies of HCT treatment
versus non-HCT treatment. As supported by this study, HCT costs are very high, having
the ability to study them in more depth impacts questions related to value of care and
ultimately healthcare decisions and policy. In addition, because the cost of HCT is high
and treatment type had a strong influence on cost, it will be important to assess cost
predictors when HCT is not present. Creating a dataset of chemotherapy only treatment
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cost would allow the opportunity to investigate health care costs of an acute leukemia
population without the dominance of HCT costs.
Further exploration of cost disparities findings related to academic medical center
and community providers, the location of the provider and the potential of differences in
use of evidence based medicine practices and quality of care.
Sub-analyses of interactions between variables were not within the scope of this
study; however, conceptually they may be important. Because of the number of variables
there are a large number of potentially important interactions. For example, given the
significant differences in provider type cost and the significance of treatment type, it
would be of interest to investigate if there is a significant interaction between the two and
to determine if treatment type is influencing the differences in provider type. In fact,
because of the strong treatment type cost finding, it would be of interest to explore its
influence on many of the significant variables. Rather than analyzing each interaction
separately, a study design incorporating the use of structural equation modeling (SEM)
should be explored. SEM would allow a simultaneous investigation of the relationships
between the variables and could be used to direct research toward analyses of the
resulting significant relationships.
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APPENDICIES
Appendix A. WHIO DMV6 Characteristics.
Table A. Characteristics of WHIO DMV6 data mart, WHIO lymphoma and leukemia,
and WHIO acute leukemia population.
Source: WHIO DMV6 training notes 1-6-2012

Variable
Population
% WI Population
Age
<18
18-64
65+
Claim service records
Medical
Pharmacy

WHIO
3,863,345

WHIO Lymphoma/
Leukemia
12,504

WHIO Acute
Leukemia
837

64.9%

.3%

.02%

29%
58%
13%

14%
34%
52%

50%
39%
12%

247,620,120
183,554,190
64,065,930

1,048,576
Not available

271,121
234,450
36,671

Claim service record by
payer type
Private/commercially
insured
Public insured
Federal Employee
Program
Medicare
Medicaid
Unknown

42%

32%

47%

58.1%
0.1%

68%

53%

Episodes of care

23.1M

18,324

8133

$64B/$34.4B

$360M (billed)

$46M/$23M

Claims $ included (Billed
cost/Std. cost)

13%
45%
1%
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Table B. Characteristics of acute leukemia analysis samples.
Variable
Sample, n

Total
638

Ancillary
138

Inpatient
201

Outpatient
497

Pharmacy
325

Professional
618

% WI
Population

.01%

.002%

.003%

.008%

.005%

.01%

Age
<18
18-64
65+

49%
39%
12%

51%
40%
9%

52%
36%
12%

52%
36%
12%

54%
34%
12%

50%
39%
11%

Male gender

56%

64%

66%

59%

62%

57%

262,524

3,869

19,683

111,488

36,671

99,410

48%
52%

46%
54%

43%
57%

48%
52%

43%
57%

47%
53%

$44M/
$21M

$672,577/
$676,253

$15M/
$7.9M

$6.9M/
$2.7M

$7.4M/
$5M

$11M/
$4.4M

Claim service
records
Claim service
record by
payer type
Commercial
Public insured

Claims $
included
(Billed/Std.
cost)
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Appendix B. WHIO Definitions.
Source: Ingenix Reporting System User Guide; WHIO training materials; Vila, et.al, Health
Disparities in Milwaukee by Socioeconomic Status, 2007.

WHIO Episode Treatment Groups (ETGs): ETGs are an illness classification method
that combines medical and pharmacy services into mutually exclusive and exhaustive
categories; providing a meaningful statistical unit representing an episode of care.
WHIO severity level: Severity is modeled per episode and uses the episode’s associated
complications and comorbidities in addition to patient age and gender.
Severity model markers, each is assigned a weight:


Age and gender



Co-morbidities and condition status



Treatments not used in severity model

Severity score:


The sum of the weights for all markers



Relative to costs for the episode

Severity level:


1-4; using score and preset ranges

WHIO standard cost: Standard cost is calculated with billed amount as input. For
inpatient services, the standard cost is based on a per diem cost calculated, primarily,
with the DRG and length of stay in addition to facility type and presence of major
surgery. Professional and ancillary services standard cost is based on Relative Value
Unit’s (RVU) from the Medicare Fee Schedule and pharmacy services standard cost uses
the average wholesale price (AWP) for the National Drug Code (NDC), adjusted by
therapeutic category and generic status. Facility and outpatient claims are based on a
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percentage of the billed amount and, in some cases, are adjusted by a WHIO-specific
conversion factor to approximate a allowed amount.
WHIO type of service: Claims are categorized based on the major type of services and
the procedure codes used in describing the service. There are four major types of service
used after assigning a service to these categories; CPT, HCPCs and Revenue codes are
used to further differentiate services at each level.
1. Ancillary
2. Facility Inpatient
3. Facility Outpatient
4. Professional
Pharmacy is the fifth service type used in the study: all claims assigned to a pharmacy
service code at any of the levels of type of service are specific to a drug cost and does not
include procedures or administration of the drug.
WHIO ZIP code: The largest 5-digit ZIP code within a region that represents a
population of >20K with the selection criteria of:


True county,



3-ZIP area excluding counties > 20K,



Full 3-ZIP area,



State

All patients within the same region of the State are assigned the same ZIP-code for deidentification purposes and the lowest level of patient geographic region identification is
the county level. A small number of patients from counties <20K are assigned to
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neighboring counties, i.e. the largest 5-digit ZIP code in a 3-ZIP area that represents a
population of >20K.
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Appendix C. WHIO DMV6 Data Information.
Source: WHIO DMV6 Impact Intelligence Training Notes, 1/6/2012
Types of Data
Data includes combined Eligibility, Medical and Pharmacy Claims and Provider
information from 15 health plans or other payers active in Wisconsin: Anthem, Dean,
Group Health Cooperative of South Central Wisconsin, Gundersen Lutheran, Health
Tradition Health Plan, Humana, MercyCare, Network Health Plan, Physicians Plus
Insurance Corporation, Security, State of Wisconsin Medicaid (FFS and HMO), United
HealthCare, Unity Health, Wisconsin Education Association Trust and Wisconsin
Physicians Service. The aggregated data does not contain any proprietary payer
information. Data does not include lab results or patient satisfaction information.
Raw data includes all activity provided to Wisconsin members, regardless of
whether the service was incurred by a Wisconsin provider, as well as all activity
performed by Wisconsin providers, regardless of whether the member resides in
Wisconsin.
Eligibility and claims information provided by data contributors is included in the
WHIO datamart; exceptions are provided below.
There are a small percentage of non-Wisconsin members that are included in the
WHIO data mart (e.g., from Border States, students, snowbirds) because they were
identified as having a complete claims experience. Claims serviced by non-Wisconsin
providers for some members of this group may be included.
All Wisconsin-related data is requested from data contributors including members
with Commercial, fully insured and full medical coverage; Commercial ASO members;
Medicare members administered by the data contributors; Medicare Supplemental
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members; other non-Commercial full-coverage members; other Commercial or nonCommercial partial-coverage members; and uncommon situations or other members. The
ability of data contributors to send data beyond their core Commercial business is
challenging and has varied by payer.
All Medicaid data is supplied by the State of Wisconsin only and include FFS and
HMO members with full medical coverage, Medicare dual members with supplemental
medical coverage through Medicaid, and a few members with Rx-only coverage.
Medicare supplemental or Medicare/Medicaid dual members are represented by
only their non-Medicare data in the data mart unless their Medicare coverage is
administered by a private carrier (i.e., Medicare Advantage members) and the private
carrier is a WHIO data contributor. When Medicare data is included for these members,
the member’s eligibility for the overlapping eligibility period will reflect their full
medical coverage through Medicare and any supplemental claim lines is categorized as
pseudo claims.
Employee Trust Fund (ETF) members and claims are included. They are identified
in the raw data but not in the final WHIO data mart to mask any member- or payerspecific information.
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Appendix D. WHIO Provider Data.
1. Provider records.
Provider information

Number of provider records

Total provider records

837

Identified Wisconsin provider records

638

Unidentified Wisconsin provider records

121

Out of state provider records

53

Unspecified provider records

25

2. U.S. State where care was provided.
U.S. States with provider records
ARIZONA
CALIFORNIA
GEORGIA
ILLINOIS
INDIANA
IOWA
KENTUCKY
MASSACHUSETTS
MICHIGAN
MINNESOTA
MISSOURI
OHIO
PENNSYLVANIA
SOUTH DAKOTA
TENNESSEE
TEXAS
WISCONSIN
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Appendix E. Dataset Coding.
1. Disease type (AML_ALL) code: patients with a diagnosis of AML or ALL present in
the database are coded as AML_ALL and included in the study population.
Disease type
AML_ALL

Disease type code
1

Other

0

2. Episode severity code:
Episode severity
Low

Episode severity code
1

Medium low

2

Medium high

3

High

4

3. Episode Treatment Group-ID:
ETG type
Leukemia without surgery

ETG-ID
85

Leukemia with surgery

86

Leukemia with active management
without surgery

87

Leukemia with active management
with surgery

88

3. Payer type code:
Payer type
Commercial
Public

Payer type code
0
1
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4. Provider type code:
Provider type
Community
Academic medical center

Provider type code
0
1

5. Service type code:
Service type
Ancillary

Service code
1

Inpatient

2

Outpatient

3

Professional

4

Pharmacy

7

6. Treatment type code:
Treatment type
Chemotherapy only
Chemotherapy and HCT

Treatment type
code
0
1

161

Appendix F. Institutional Review Board Approval Letter.
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